The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon alfa is a Drug named entity .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon is a Drug named entity .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@vascular retinopathy is an Adverse-Effect named entity .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@anterior ischemic optic neuropathy is an Adverse-Effect named entity .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@initiating is not a named entity .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@retinopathy is not a named entity .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@anterior is not a named entity .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@of interferon - associated is not a named entity .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@associated vascular is not a named entity .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@onset of is not a named entity .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@amitriptyline is a Drug named entity .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@neuroleptic malignant syndrome is an Adverse-Effect named entity .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@lithium carbonate is a Drug named entity .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@lithium is not a named entity .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@carbonate is not a named entity .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@on amitriptyline and is not a named entity .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@patient on is not a named entity .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@increased serum thyroid - stimulating hormone is an Adverse-Effect named entity .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@levothyroxine is a Drug named entity .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@stable is not a named entity .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@hypothyroidism is not a named entity .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@SUMMARIES is not a named entity .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@switching is not a named entity .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@TSH is not a named entity .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@product is not a named entity .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@after switching from 1 levothyroxine product is not a named entity .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@arrhythmia is an Adverse-Effect named entity .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@adenosine is a Drug named entity .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@dangerous is not a named entity .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@Evidence is not a named entity .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@worsening is not a named entity .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@flutter is not a named entity .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@adenosine is a Drug named entity .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@alterations in heart rate is an Adverse-Effect named entity .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@alterations is not a named entity .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@flutter is not a named entity .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@Life is not a named entity .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@after the use of is not a named entity .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@temporary amnesia is an Adverse-Effect named entity .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@disorientation is an Adverse-Effect named entity .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@propranolol is a Drug named entity .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@temporary is not a named entity .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@analogous is not a named entity .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@amnesia is not a named entity .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@Comparable is not a named entity .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@disorientation and is not a named entity .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@propafenone is a Drug named entity .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@transient global amnesia is an Adverse-Effect named entity .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@amnesia is not a named entity .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@global is not a named entity .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@of transient global is not a named entity .
Probable propafenone - induced transient global amnesia .@_@transient global amnesia is an Adverse-Effect named entity .
Probable propafenone - induced transient global amnesia .@_@propafenone is a Drug named entity .
Probable propafenone - induced transient global amnesia .@_@global is not a named entity .
Probable propafenone - induced transient global amnesia .@_@Probable is not a named entity .
Probable propafenone - induced transient global amnesia .@_@amnesia is not a named entity .
Probable propafenone - induced transient global amnesia .@_@induced transient global is not a named entity .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@aspirin is a Drug named entity .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@acute subdural haematoma is an Adverse-Effect named entity .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@haematoma is not a named entity .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@meningioma is not a named entity .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@subdural is not a named entity .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@angiomatous is not a named entity .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@spontaneously is not a named entity .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@originating is not a named entity .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@prophylactic is not a named entity .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@haematoma originating spontaneously is not a named entity .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@Intracranial haemorrhage is an Adverse-Effect named entity .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@aspirin is a Drug named entity .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@prophylaxis is not a named entity .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@Intracranial is not a named entity .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@haemorrhage is not a named entity .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@meningioma is not a named entity .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@a meningioma is not a named entity .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@akathisia is an Adverse-Effect named entity .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@fluvoxamine is a Drug named entity .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@mianserin is not a named entity .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@compulsive is not a named entity .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@obsessive is not a named entity .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@Beneficial is not a named entity .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@sertraline is a Drug named entity .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@Extrapyramidal side effects is an Adverse-Effect named entity .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@fluoxetine is a Drug named entity .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@SSRIs is not a named entity .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@OCD is not a named entity .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@Extrapyramidal is not a named entity .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@reuptake is not a named entity .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@i.e. is not a named entity .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@fluoxetine and sertraline is not a named entity .
However , the occurrence and management of akathisia induced by fluvoxamine have not been described .@_@fluvoxamine is a Drug named entity .
However , the occurrence and management of akathisia induced by fluvoxamine have not been described .@_@akathisia is an Adverse-Effect named entity .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@fluvoxamine is a Drug named entity .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@akathisia is an Adverse-Effect named entity .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@anticholinergic is not a named entity .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@mianserin is not a named entity .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@OCD is not a named entity .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@5-HT2A/5-HT2C is not a named entity .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@biperiden is not a named entity .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@partially is not a named entity .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@interstitial pneumonitis is an Adverse-Effect named entity .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@bleomycin is a Drug named entity .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@testicular is not a named entity .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@42 is not a named entity .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@that included is not a named entity .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@lung toxicity is an Adverse-Effect named entity .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@bleomycin is a Drug named entity .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@reversal is not a named entity .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@dose corticosteroids is not a named entity .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@lung toxicity is an Adverse-Effect named entity .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@bleomycin is a Drug named entity .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@aggressively is not a named entity .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@treated aggressively is not a named entity .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@neutropenia is an Adverse-Effect named entity .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@gold is a Drug named entity .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@CSF is not a named entity .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@Reversal is not a named entity .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@severe neutropenia is an Adverse-Effect named entity .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@gold is a Drug named entity .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@reducing is not a named entity .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@CSF is not a named entity .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@duration is not a named entity .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@overcome is not a named entity .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@salts is not a named entity .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@have successfully is not a named entity .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@amphotericin B is a Drug named entity .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@cardiac arrest is an Adverse-Effect named entity .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@Arrhythmias is an Adverse-Effect named entity .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@technique is not a named entity .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@arrest is not a named entity .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@effective is not a named entity .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@prevent is not a named entity .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@them is not a named entity .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@Arrhythmias and is not a named entity .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@during amphotericin is not a named entity .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@cardiac arrhythmia is an Adverse-Effect named entity .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@amphotericin B is a Drug named entity .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@prevents is not a named entity .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@imbalance is not a named entity .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@electrolyte is not a named entity .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@arrhythmia is not a named entity .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@Correction is not a named entity .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@administration . is not a named entity .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@during amphotericin is not a named entity .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@amphotericin is a Drug named entity .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@cardiac arrest is an Adverse-Effect named entity .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@spite is not a named entity .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@tolerating is not a named entity .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@arrest is not a named entity .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@stibogluconate is not a named entity .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@azar is not a named entity .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@saw is not a named entity .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@kala is not a named entity .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@patients with is not a named entity .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@angry outbursts is an Adverse-Effect named entity .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@lithium is a Drug named entity .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@irritability is an Adverse-Effect named entity .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@angry is not a named entity .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@PTSD is not a named entity .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@veterans is not a named entity .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@problems is not a named entity .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@illustrate is not a named entity .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@outbursts is not a named entity .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@or angry is not a named entity .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@transient thyrotoxicosis is an Adverse-Effect named entity .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@interferon is a Drug named entity .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@Graves ' hyperthyroidism is an Adverse-Effect named entity .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@hyperthyroidism is not a named entity .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@thyrotoxicosis is not a named entity .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@chronic hepatitis type is not a named entity .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@hyperthyroidism following is not a named entity .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@Graves ' hyperthyroidism is an Adverse-Effect named entity .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@IFN is a Drug named entity .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@thyrotoxicosis is not a named entity .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@sequential is not a named entity .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@hyperthyroidism is not a named entity .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@manifestation is not a named entity .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@autoantibodies is not a named entity .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@TSH is not a named entity .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@then is not a named entity .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@appearance is not a named entity .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@sequential manifestation from is not a named entity .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@interferon is a Drug named entity .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@IFN is a Drug named entity .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@Graves ' hyperthyroidism is an Adverse-Effect named entity .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@interferon ( IFN is not a named entity .
Acute INH neurotoxicity was not suspected on the first admission ; however , when readmitted 4 weeks later with another seizure , the diagnosis of acute INH neurotoxicity was made .@_@neurotoxicity is an Adverse-Effect named entity .
Acute INH neurotoxicity was not suspected on the first admission ; however , when readmitted 4 weeks later with another seizure , the diagnosis of acute INH neurotoxicity was made .@_@INH is a Drug named entity .
Acute INH neurotoxicity was not suspected on the first admission ; however , when readmitted 4 weeks later with another seizure , the diagnosis of acute INH neurotoxicity was made .@_@admission is not a named entity .
Acute INH neurotoxicity was not suspected on the first admission ; however , when readmitted 4 weeks later with another seizure , the diagnosis of acute INH neurotoxicity was made .@_@readmitted is not a named entity .
Acute INH neurotoxicity was not suspected on the first admission ; however , when readmitted 4 weeks later with another seizure , the diagnosis of acute INH neurotoxicity was made .@_@made is not a named entity .
Acute isoniazid neurotoxicity in an urban hospital .@_@isoniazid is a Drug named entity .
Acute isoniazid neurotoxicity in an urban hospital .@_@neurotoxicity is an Adverse-Effect named entity .
Acute isoniazid neurotoxicity in an urban hospital .@_@urban is not a named entity .
Acute isoniazid neurotoxicity in an urban hospital .@_@hospital is not a named entity .
CONCLUSIONS : We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City .@_@neurotoxicity is an Adverse-Effect named entity .
CONCLUSIONS : We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City .@_@INH is a Drug named entity .
CONCLUSIONS : We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City .@_@York is not a named entity .
CONCLUSIONS : We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City .@_@resurgence is not a named entity .
CONCLUSIONS : We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City .@_@New is not a named entity .
CONCLUSIONS : We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City .@_@TB is not a named entity .
CONCLUSIONS : We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City .@_@City is not a named entity .
In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .@_@INH is a Drug named entity .
In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .@_@seizures is an Adverse-Effect named entity .
In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .@_@access is not a named entity .
In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .@_@otherwise is not a named entity .
In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .@_@unless is not a named entity .
In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .@_@proved is not a named entity .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@INH is a Drug named entity .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@neurotoxicity is an Adverse-Effect named entity .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@isoniazid is a Drug named entity .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@municipal is not a named entity .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@inner is not a named entity .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@appearing is not a named entity .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@hospital is not a named entity .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@OBJECTIVES is not a named entity .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@city is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@INH is a Drug named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@refractory seizures is an Adverse-Effect named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@antidote is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@specific is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@similarly is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@experiencing is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@trends is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@areas is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@Parenteral is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@TB is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@emergency is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@pyridoxine is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@every is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@department is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@available is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@readily is not a named entity .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@readily available is not a named entity .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@INH is a Drug named entity .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@neurotoxicity is an Adverse-Effect named entity .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@1991 is not a named entity .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@seven is not a named entity .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@institution is not a named entity .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@1985 is not a named entity .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@1990 is not a named entity .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@At is not a named entity .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@whereas is not a named entity .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@through is not a named entity .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@1993 is not a named entity .
Arterial hypertension associated with topical ocular use of phenylephrine in dogs .@_@phenylephrine is a Drug named entity .
Arterial hypertension associated with topical ocular use of phenylephrine in dogs .@_@Arterial hypertension is an Adverse-Effect named entity .
Arterial hypertension associated with topical ocular use of phenylephrine in dogs .@_@Arterial is not a named entity .
Arterial hypertension associated with topical ocular use of phenylephrine in dogs .@_@dogs is not a named entity .
Arterial hypertension associated with topical ocular use of phenylephrine in dogs .@_@ocular use is not a named entity .
CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .@_@progestin is a Drug named entity .
CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .@_@Squamous metaplasia is an Adverse-Effect named entity .
CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .@_@consequence is not a named entity .
CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .@_@Squamous is not a named entity .
CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .@_@metaplasia is not a named entity .
CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .@_@appears to is not a named entity .
OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .@_@squamous metaplasia within endometrial glands is an Adverse-Effect named entity .
OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .@_@progestin is a Drug named entity .
OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .@_@metaplasia is not a named entity .
OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .@_@squamous is not a named entity .
OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .@_@finding is not a named entity .
OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .@_@glands is not a named entity .
OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .@_@glands occurring as a result is not a named entity .
RESULTS : Extensive squamous metaplasia was found in endometrial glands following progestin therapy .@_@squamous metaplasia is an Adverse-Effect named entity .
RESULTS : Extensive squamous metaplasia was found in endometrial glands following progestin therapy .@_@progestin is a Drug named entity .
RESULTS : Extensive squamous metaplasia was found in endometrial glands following progestin therapy .@_@metaplasia is not a named entity .
RESULTS : Extensive squamous metaplasia was found in endometrial glands following progestin therapy .@_@glands is not a named entity .
RESULTS : Extensive squamous metaplasia was found in endometrial glands following progestin therapy .@_@Extensive is not a named entity .
RESULTS : Extensive squamous metaplasia was found in endometrial glands following progestin therapy .@_@was found is not a named entity .
Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .@_@furosemide is a Drug named entity .
Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .@_@Fever is an Adverse-Effect named entity .
Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .@_@reintroduction is not a named entity .
Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .@_@proved is not a named entity .
Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .@_@recurred is not a named entity .
Furosemide - associated fever .@_@fever is an Adverse-Effect named entity .
Furosemide - associated fever .@_@Furosemide is a Drug named entity .
The dose - limiting toxicity of KW-2149 is pulmonary toxicity .@_@pulmonary toxicity is an Adverse-Effect named entity .
The dose - limiting toxicity of KW-2149 is pulmonary toxicity .@_@KW-2149 is a Drug named entity .
The dose - limiting toxicity of KW-2149 is pulmonary toxicity .@_@limiting is not a named entity .
The dose - limiting toxicity of KW-2149 is pulmonary toxicity .@_@limiting toxicity is not a named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@cyclophosphamide is a Drug named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@ifosfamide is a Drug named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@Musculoskeletal complaints is an Adverse-Effect named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@44 is not a named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@complaints is not a named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@tumors is not a named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@relapsed is not a named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@Wilms is not a named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@derivative is not a named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@Musculoskeletal is not a named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@9 is not a named entity .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@for relapsed is not a named entity .
Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .@_@Fanconi syndrome is an Adverse-Effect named entity .
Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .@_@ifosfamide is a Drug named entity .
Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .@_@Fanconi is not a named entity .
Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .@_@Recognition is not a named entity .
Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .@_@managing is not a named entity .
Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .@_@oncology is not a named entity .
Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .@_@oncology patients is not a named entity .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@hepatotoxicity is an Adverse-Effect named entity .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@benzarone is a Drug named entity .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@cirrhosis is an Adverse-Effect named entity .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@( sub)fulminant hepatitis is an Adverse-Effect named entity .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@far is not a named entity .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@comprise is not a named entity .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@so is not a named entity .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@sub)fulminant is not a named entity .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@constitute is not a named entity .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@reported so far is not a named entity .
Severe hepatotoxicity related to benzarone : a report of three cases with two fatalities .@_@benzarone is a Drug named entity .
Severe hepatotoxicity related to benzarone : a report of three cases with two fatalities .@_@Severe hepatotoxicity is an Adverse-Effect named entity .
Severe hepatotoxicity related to benzarone : a report of three cases with two fatalities .@_@hepatotoxicity is not a named entity .
Severe hepatotoxicity related to benzarone : a report of three cases with two fatalities .@_@fatalities is not a named entity .
Severe hepatotoxicity related to benzarone : a report of three cases with two fatalities .@_@: a is not a named entity .
We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .@_@benzarone is a Drug named entity .
We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .@_@severe hepatotoxicity is an Adverse-Effect named entity .
We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .@_@hepatotoxicity is not a named entity .
We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .@_@derivative is not a named entity .
We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .@_@benzofuran is not a named entity .
We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .@_@cases of is not a named entity .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@benzarone is a Drug named entity .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@severe chronic active hepatitis is an Adverse-Effect named entity .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@hepatotoxicity is an Adverse-Effect named entity .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@resembles is not a named entity .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@stress is not a named entity .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@stress the potential of is not a named entity .
Case study : a modified topical treatment regimen for sodium warfarin - induced necrotizing fasciitis .@_@necrotizing fasciitis is an Adverse-Effect named entity .
Case study : a modified topical treatment regimen for sodium warfarin - induced necrotizing fasciitis .@_@warfarin is a Drug named entity .
Case study : a modified topical treatment regimen for sodium warfarin - induced necrotizing fasciitis .@_@modified is not a named entity .
Case study : a modified topical treatment regimen for sodium warfarin - induced necrotizing fasciitis .@_@necrotizing is not a named entity .
Case study : a modified topical treatment regimen for sodium warfarin - induced necrotizing fasciitis .@_@fasciitis is not a named entity .
Case study : a modified topical treatment regimen for sodium warfarin - induced necrotizing fasciitis .@_@regimen for is not a named entity .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@myonecrosis is an Adverse-Effect named entity .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@necrotizing fasciitis is an Adverse-Effect named entity .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@sodium warfarin is a Drug named entity .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@warfarin is not a named entity .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@necrotizing is not a named entity .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@fasciitis is not a named entity .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@an atypical is not a named entity .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@case of is not a named entity .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@severe hypoglycaemia is an Adverse-Effect named entity .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@mefloquine is a Drug named entity .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@manage is not a named entity .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@malarial is not a named entity .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@cachectic is not a named entity .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@diarrhoea is not a named entity .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@protracted is not a named entity .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@hypoglycaemia is not a named entity .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@cachectic patients is not a named entity .
Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .@_@mefloquine is a Drug named entity .
Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .@_@hypoglycaemia is an Adverse-Effect named entity .
Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .@_@quinine is not a named entity .
Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .@_@analogues is not a named entity .
Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .@_@triggering is not a named entity .
Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .@_@Mechanisms is not a named entity .
Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .@_@malarial is not a named entity .
Mefloquine - associated hypoglycaemia in a cachectic AIDS patient .@_@Mefloquine is a Drug named entity .
Mefloquine - associated hypoglycaemia in a cachectic AIDS patient .@_@hypoglycaemia is an Adverse-Effect named entity .
Mefloquine - associated hypoglycaemia in a cachectic AIDS patient .@_@cachectic is not a named entity .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@iatrogenic hypoglycaemia is an Adverse-Effect named entity .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@Quinine is a Drug named entity .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@quinidine is a Drug named entity .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@iatrogenic is not a named entity .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@hypoglycaemia is not a named entity .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@excessive is not a named entity .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@isomer is not a named entity .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@secretion is not a named entity .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@quinidine are is not a named entity .
We report a case of hypoglycaemia after mefloquine therapy ( 1,500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea .@_@mefloquine is a Drug named entity .
We report a case of hypoglycaemia after mefloquine therapy ( 1,500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea .@_@hypoglycaemia is an Adverse-Effect named entity .
We report a case of hypoglycaemia after mefloquine therapy ( 1,500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea .@_@diarrhoea is not a named entity .
We report a case of hypoglycaemia after mefloquine therapy ( 1,500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea .@_@protracted is not a named entity .
We report a case of hypoglycaemia after mefloquine therapy ( 1,500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea .@_@cryptosporidiasis is not a named entity .
We report a case of hypoglycaemia after mefloquine therapy ( 1,500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea .@_@cachectic is not a named entity .
We report a case of hypoglycaemia after mefloquine therapy ( 1,500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea .@_@1,500 is not a named entity .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@sumatriptan is a Drug named entity .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@coronary artery vasospasm is an Adverse-Effect named entity .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@evaluated is not a named entity .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@Because is not a named entity .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@carefully is not a named entity .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@cardiovascular is not a named entity .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@vasospasm is not a named entity .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@artery disease should is not a named entity .
Cardiac arrest following use of sumatriptan .@_@Cardiac arrest is an Adverse-Effect named entity .
Cardiac arrest following use of sumatriptan .@_@sumatriptan is a Drug named entity .
Cardiac arrest following use of sumatriptan .@_@Cardiac is not a named entity .
Cardiac arrest following use of sumatriptan .@_@arrest is not a named entity .
Cardiac arrest following use of sumatriptan .@_@arrest following is not a named entity .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@cardiac arrest is an Adverse-Effect named entity .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@sumatriptan is a Drug named entity .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@occult is not a named entity .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@arrest is not a named entity .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@35-year is not a named entity .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@migraine is not a named entity .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@minutes is not a named entity .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@who experienced is not a named entity .
Sotalol - induced bradycardia reversed by glucagon .@_@bradycardia is an Adverse-Effect named entity .
Sotalol - induced bradycardia reversed by glucagon .@_@Sotalol is a Drug named entity .
Sotalol - induced bradycardia reversed by glucagon .@_@reversed is not a named entity .
Sotalol - induced bradycardia reversed by glucagon .@_@glucagon is not a named entity .
We present a case of sotalol - induced bradycardia reversed by glucagon .@_@bradycardia is an Adverse-Effect named entity .
We present a case of sotalol - induced bradycardia reversed by glucagon .@_@sotalol is a Drug named entity .
We present a case of sotalol - induced bradycardia reversed by glucagon .@_@reversed is not a named entity .
We present a case of sotalol - induced bradycardia reversed by glucagon .@_@glucagon is not a named entity .
Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer : a report of a case .@_@tamoxifen is a Drug named entity .
Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer : a report of a case .@_@Secretory endometrial adenocarcinoma is an Adverse-Effect named entity .
Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer : a report of a case .@_@Secretory is not a named entity .
Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer : a report of a case .@_@in a patient is not a named entity .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@low - grade endometrial carcinoma is an Adverse-Effect named entity .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@uterine neoplasia is an Adverse-Effect named entity .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@tamoxifen is a Drug named entity .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@neoplasia is not a named entity .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@spectrum is not a named entity .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@uterine is not a named entity .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@pattern is not a named entity .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@adds is not a named entity .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@uterine neoplasia associated with tamoxifen is not a named entity .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@therapy . is not a named entity .
We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use .@_@secretory carcinoma of the endometrium is an Adverse-Effect named entity .
We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use .@_@tamoxifen is a Drug named entity .
We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use .@_@endometrium is not a named entity .
We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use .@_@secretory is not a named entity .
We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use .@_@believe that this is the is not a named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@tamoxifen is a Drug named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@endometrial adenocarcinoma of the secretory type is an Adverse-Effect named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@differentiated is not a named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@invasion is not a named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@Grade is not a named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@Well is not a named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@myometrial is not a named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@minimal is not a named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@postmenopausal is not a named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@mastectomy is not a named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@secretory is not a named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@FIGO is not a named entity .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@postmenopausal patient on tamoxifen therapy 5 is not a named entity .
Esophageal candidiasis following omeprazole therapy : a report of two cases .@_@omeprazole is a Drug named entity .
Esophageal candidiasis following omeprazole therapy : a report of two cases .@_@Esophageal candidiasis is an Adverse-Effect named entity .
Esophageal candidiasis following omeprazole therapy : a report of two cases .@_@Esophageal is not a named entity .
Esophageal candidiasis following omeprazole therapy : a report of two cases .@_@candidiasis is not a named entity .
Esophageal candidiasis following omeprazole therapy : a report of two cases .@_@a report is not a named entity .
Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .@_@omeprazole is a Drug named entity .
Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .@_@Esophageal candidiasis is an Adverse-Effect named entity .
Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .@_@endoscopy is not a named entity .
Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .@_@candidiasis is not a named entity .
Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .@_@Esophageal is not a named entity .
Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .@_@was diagnosed is not a named entity .
High - grade atrioventricular block during dipyridamole stress testing .@_@High - grade atrioventricular block is an Adverse-Effect named entity .
High - grade atrioventricular block during dipyridamole stress testing .@_@dipyridamole is a Drug named entity .
High - grade atrioventricular block during dipyridamole stress testing .@_@High is not a named entity .
High - grade atrioventricular block during dipyridamole stress testing .@_@testing is not a named entity .
High - grade atrioventricular block during dipyridamole stress testing .@_@atrioventricular is not a named entity .
High - grade atrioventricular block during dipyridamole stress testing .@_@stress is not a named entity .
High - grade atrioventricular block during dipyridamole stress testing .@_@atrioventricular block during dipyridamole stress is not a named entity .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@dipyridamole is a Drug named entity .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@high - grade atrioventricular ( AV ) block is an Adverse-Effect named entity .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@responded is not a named entity .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@atropine is not a named entity .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@promptly is not a named entity .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@AV is not a named entity .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@aminophylline is not a named entity .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@atrioventricular is not a named entity .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@atrioventricular ( AV ) block that responded promptly is not a named entity .
Aggressive management of doxorubicin - induced cardiomyopathy associated with ' low ' doses of doxorubicin .@_@cardiomyopathy is an Adverse-Effect named entity .
Aggressive management of doxorubicin - induced cardiomyopathy associated with ' low ' doses of doxorubicin .@_@doxorubicin is a Drug named entity .
Aggressive management of doxorubicin - induced cardiomyopathy associated with ' low ' doses of doxorubicin .@_@Aggressive is not a named entity .
There is a dose - effect relationship between doxorubicin and the incidence of symptomatic cardiac failure .@_@doxorubicin is a Drug named entity .
There is a dose - effect relationship between doxorubicin and the incidence of symptomatic cardiac failure .@_@symptomatic cardiac failure is an Adverse-Effect named entity .
There is a dose - effect relationship between doxorubicin and the incidence of symptomatic cardiac failure .@_@effect relationship between is not a named entity .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@endometriosis is an Adverse-Effect named entity .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@tamoxifen is a Drug named entity .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@Ovarian endometrioid carcinoma is an Adverse-Effect named entity .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@Ovarian is not a named entity .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@endometrioid is not a named entity .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@postmenopausal is not a named entity .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@review of the is not a named entity .
The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .@_@ovarian endometrioid carcinoma is an Adverse-Effect named entity .
The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .@_@tamoxifen is a Drug named entity .
The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .@_@unopposed is not a named entity .
The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .@_@estrogen is not a named entity .
The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .@_@endometrioid is not a named entity .
The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .@_@stimulation is not a named entity .
The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .@_@of ovarian endometrioid is not a named entity .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@ovarian endometrioid carcinoma is an Adverse-Effect named entity .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@endometriosis is an Adverse-Effect named entity .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@tamoxifen is a Drug named entity .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@postmenopausal is not a named entity .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@endometrioid is not a named entity .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@in a postmenopausal is not a named entity .
Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .@_@Cerebral demyelinating disease is an Adverse-Effect named entity .
Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .@_@levamisole is a Drug named entity .
Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .@_@Cerebral is not a named entity .
Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .@_@adjuvant is not a named entity .
Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .@_@demyelinating is not a named entity .
Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .@_@melanoma is not a named entity .
Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .@_@demyelinating disease developed is not a named entity .
Multifocal inflammatory leukoencephalopathy associated with levamisole therapy .@_@levamisole is a Drug named entity .
Multifocal inflammatory leukoencephalopathy associated with levamisole therapy .@_@Multifocal inflammatory leukoencephalopathy is an Adverse-Effect named entity .
Multifocal inflammatory leukoencephalopathy associated with levamisole therapy .@_@Multifocal is not a named entity .
Multifocal inflammatory leukoencephalopathy associated with levamisole therapy .@_@leukoencephalopathy is not a named entity .
Multifocal inflammatory leukoencephalopathy associated with levamisole therapy .@_@inflammatory leukoencephalopathy associated is not a named entity .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@5-fluorouracil is a Drug named entity .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@leukoencephalopathy is an Adverse-Effect named entity .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@levamisole is a Drug named entity .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@partly is not a named entity .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@least is not a named entity .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@Observations is not a named entity .
A case of noncardiogenic pulmonary edema by ethanolamine oleate .@_@noncardiogenic pulmonary edema is an Adverse-Effect named entity .
A case of noncardiogenic pulmonary edema by ethanolamine oleate .@_@ethanolamine oleate is a Drug named entity .
A case of noncardiogenic pulmonary edema by ethanolamine oleate .@_@noncardiogenic is not a named entity .
A case of noncardiogenic pulmonary edema by ethanolamine oleate .@_@ethanolamine is not a named entity .
A case of noncardiogenic pulmonary edema by ethanolamine oleate .@_@oleate is not a named entity .
A case of noncardiogenic pulmonary edema by ethanolamine oleate .@_@ethanolamine oleate . is not a named entity .
A case of noncardiogenic pulmonary edema by ethanolamine oleate .@_@noncardiogenic pulmonary is not a named entity .
However , EO - induced noncardiogenic pulmonary edema has not been reported in human .@_@EO is a Drug named entity .
However , EO - induced noncardiogenic pulmonary edema has not been reported in human .@_@noncardiogenic pulmonary edema is an Adverse-Effect named entity .
However , EO - induced noncardiogenic pulmonary edema has not been reported in human .@_@noncardiogenic is not a named entity .
However , EO - induced noncardiogenic pulmonary edema has not been reported in human .@_@EO - induced is not a named entity .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@noncardiogenic pulmonary edema is an Adverse-Effect named entity .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@EO is a Drug named entity .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@noncardiogenic is not a named entity .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@trial is not a named entity .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@sclerosing is not a named entity .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@varix is not a named entity .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@esophageal is not a named entity .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@esophageal varix . is not a named entity .
Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .@_@acute renal failure is an Adverse-Effect named entity .
Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .@_@gentamicin sulfate is a Drug named entity .
Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .@_@sulfate is not a named entity .
Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .@_@gentamicin is not a named entity .
Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .@_@Five is not a named entity .
Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .@_@in whom only is not a named entity .
Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .@_@Five patients is not a named entity .
Gentamicin - associated acute renal failure .@_@Gentamicin is a Drug named entity .
Gentamicin - associated acute renal failure .@_@acute renal failure is an Adverse-Effect named entity .
Gentamicin - associated acute renal failure .@_@renal failure . is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@gentamicin is a Drug named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@Renal failure is an Adverse-Effect named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@mEq is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@clearances is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@urine is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@ratios is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@min is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@creatinine is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@liter is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@cylindruria is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@beginning is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@proteinuria is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@17 is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@60 is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@ml is not a named entity .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@, proteinuria is not a named entity .
A 15-year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .@_@phenytoin is a Drug named entity .
A 15-year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .@_@unilateral gingival hyperplasia is an Adverse-Effect named entity .
A 15-year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .@_@gingival is not a named entity .
A 15-year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .@_@15-year is not a named entity .
A 15-year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .@_@unilateral is not a named entity .
A 15-year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .@_@- up of is not a named entity .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@PHT is a Drug named entity .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@phenytoin is a Drug named entity .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@unilateral gingival hyperplasia is an Adverse-Effect named entity .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@unilateral is not a named entity .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@15-year is not a named entity .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@aim is not a named entity .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@INTRODUCTION is not a named entity .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@gingival is not a named entity .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@GH is not a named entity .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@report is to is not a named entity .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@aminotriazole is a Drug named entity .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@generalized cutaneous sclerosis is an Adverse-Effect named entity .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@diuron is a Drug named entity .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@bromocil is a Drug named entity .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@containing is not a named entity .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@oesophageal is not a named entity .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@herbicides is not a named entity .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@to herbicides containing is not a named entity .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@cardiac toxicity is an Adverse-Effect named entity .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@hypokalemia is an Adverse-Effect named entity .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@Albuterol is a Drug named entity .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@briefly is not a named entity .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@toxicity are is not a named entity .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@Hypokalemia is an Adverse-Effect named entity .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@albuterol is a Drug named entity .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@salbutamol is a Drug named entity .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@neubulized is not a named entity .
The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented .@_@hypokalemic is an Adverse-Effect named entity .
The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented .@_@albuterol is a Drug named entity .
The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented .@_@inhalation is not a named entity .
The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented .@_@asthmatic is not a named entity .
Propoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature .@_@wide complex dysrhythmia is an Adverse-Effect named entity .
Propoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature .@_@Propoxyphene is a Drug named entity .
Propoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature .@_@bicarbonate is not a named entity .
Propoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature .@_@wide is not a named entity .
Propoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature .@_@responsive is not a named entity .
Propoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature .@_@dysrhythmia is not a named entity .
Propoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature .@_@therapy has not is not a named entity .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@wide QRS complex dysrhythmia is an Adverse-Effect named entity .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@Propoxyphene is a Drug named entity .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@QRS is not a named entity .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@responsive is not a named entity .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@dysrhythmia is not a named entity .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@wide is not a named entity .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@bicarbonate is not a named entity .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@induced wide QRS complex is not a named entity .
Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .@_@nephrotoxicity syndrome is an Adverse-Effect named entity .
Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .@_@mannitol is a Drug named entity .
Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .@_@postulate is not a named entity .
Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .@_@hemodialysis is not a named entity .
Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .@_@nephrotoxicity is not a named entity .
Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .@_@role of is not a named entity .
Hemodialysis should be performed for rapid reversal of mannitol - induced ARF .@_@mannitol is a Drug named entity .
Hemodialysis should be performed for rapid reversal of mannitol - induced ARF .@_@ARF is an Adverse-Effect named entity .
Hemodialysis should be performed for rapid reversal of mannitol - induced ARF .@_@performed is not a named entity .
Hemodialysis should be performed for rapid reversal of mannitol - induced ARF .@_@reversal is not a named entity .
Hemodialysis should be performed for rapid reversal of mannitol - induced ARF .@_@Hemodialysis is not a named entity .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@ARF is an Adverse-Effect named entity .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@acute renal failure is an Adverse-Effect named entity .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@mannitol is a Drug named entity .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@High is not a named entity .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@various is not a named entity .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@settings is not a named entity .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@renal failure ( is not a named entity .
Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .@_@ARF is an Adverse-Effect named entity .
Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .@_@Mannitol is a Drug named entity .
Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .@_@promptly is not a named entity .
Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .@_@anuria is not a named entity .
Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .@_@hemodialysis is not a named entity .
Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .@_@responds is not a named entity .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@nephrotoxicity is an Adverse-Effect named entity .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@mannitol is a Drug named entity .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@ARF is an Adverse-Effect named entity .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@dialysis is not a named entity .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@mechanism(s is not a named entity .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@receive is not a named entity .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@did is not a named entity .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@mannitol is a Drug named entity .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@anuric ARF is an Adverse-Effect named entity .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@ARF is not a named entity .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@responded is not a named entity .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@anuric is not a named entity .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@angle is not a named entity .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@hemodialysis is not a named entity .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@narrow is not a named entity .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@readily is not a named entity .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@acute hemodialysis is not a named entity .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@fluphenazine decanoate is a Drug named entity .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@extrapyramidal side effects is an Adverse-Effect named entity .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@IBZM is not a named entity .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@decanoate is not a named entity .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@SPECT is not a named entity .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@means is not a named entity .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@evaluated is not a named entity .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@extrapyramidal is not a named entity .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@fluphenazine is not a named entity .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@IBZM - SPECT is not a named entity .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@patients with is not a named entity .
Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .@_@benzodiazepine is a Drug named entity .
Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .@_@sedation is an Adverse-Effect named entity .
Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .@_@ECT is not a named entity .
Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .@_@reversal is not a named entity .
Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .@_@Flumazenil is not a named entity .
Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .@_@anxiety is not a named entity .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@quinapril is a Drug named entity .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@irritating cough is an Adverse-Effect named entity .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@dry is not a named entity .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@68-year is not a named entity .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@irritating is not a named entity .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@essential is not a named entity .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@cough is not a named entity .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@within one is not a named entity .
Cough induced by quinapril with resolution after changing to fosinopril .@_@Cough is an Adverse-Effect named entity .
Cough induced by quinapril with resolution after changing to fosinopril .@_@quinapril is a Drug named entity .
Cough induced by quinapril with resolution after changing to fosinopril .@_@changing is not a named entity .
Cough induced by quinapril with resolution after changing to fosinopril .@_@fosinopril is not a named entity .
OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .@_@quinapril is a Drug named entity .
OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .@_@cough is an Adverse-Effect named entity .
OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .@_@converting is not a named entity .
OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .@_@nonproductive is not a named entity .
OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .@_@ACE is not a named entity .
OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .@_@fosinopril is not a named entity .
OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .@_@angiotensin is not a named entity .
The cough continued for the duration of therapy with quinapril .@_@quinapril is a Drug named entity .
The cough continued for the duration of therapy with quinapril .@_@cough is an Adverse-Effect named entity .
The cough continued for the duration of therapy with quinapril .@_@duration is not a named entity .
We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .@_@quinapril is a Drug named entity .
We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .@_@cough is an Adverse-Effect named entity .
We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .@_@essential is not a named entity .
We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .@_@changing is not a named entity .
We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .@_@fosinopril is not a named entity .
We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .@_@ACE is not a named entity .
We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .@_@alternative is not a named entity .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@PSL is a Drug named entity .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@Fracture of the femoral neck is an Adverse-Effect named entity .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@fracture is not a named entity .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@neck is not a named entity .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@Fracture is not a named entity .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@femoral is not a named entity .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@uncertain is not a named entity .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@one patient during PSL therapy is not a named entity .
Cefuroxime - induced acute renal failure .@_@acute renal failure is an Adverse-Effect named entity .
Cefuroxime - induced acute renal failure .@_@Cefuroxime is a Drug named entity .
Cefuroxime - induced acute renal failure .@_@Cefuroxime - induced is not a named entity .
In our patient , DIAN possibly was related to cefuroxime , but the patient did not experience associated allergic symptoms .@_@cefuroxime is a Drug named entity .
In our patient , DIAN possibly was related to cefuroxime , but the patient did not experience associated allergic symptoms .@_@DIAN is an Adverse-Effect named entity .
In our patient , DIAN possibly was related to cefuroxime , but the patient did not experience associated allergic symptoms .@_@did is not a named entity .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@renal deterioration is an Adverse-Effect named entity .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@cefuroxime is a Drug named entity .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@temporal is not a named entity .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@supported is not a named entity .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@repeated is not a named entity .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@improvement is not a named entity .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@deterioration is not a named entity .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@deterioration during is not a named entity .
This is the first reported case of suspected DIAN due to cefuroxime .@_@cefuroxime is a Drug named entity .
This is the first reported case of suspected DIAN due to cefuroxime .@_@DIAN is an Adverse-Effect named entity .
A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .@_@phenytoin is a Drug named entity .
A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .@_@basilar invagination is an Adverse-Effect named entity .
A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .@_@arisen is not a named entity .
A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .@_@basilar is not a named entity .
A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .@_@intrauterine is not a named entity .
A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .@_@invagination is not a named entity .
A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .@_@from the is not a named entity .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@phenytoin is a Drug named entity .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@Basilar invagination is an Adverse-Effect named entity .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@mid - line skeletal abnormalities is an Adverse-Effect named entity .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@invagination is not a named entity .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@line is not a named entity .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@Basilar is not a named entity .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@utero is not a named entity .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@mid is not a named entity .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@skeletal is not a named entity .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@abnormalities due is not a named entity .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@Basilar invagination and mid - is not a named entity .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@craniocervical abnormality is an Adverse-Effect named entity .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@phenytoin is a Drug named entity .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@stem is not a named entity .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@His is not a named entity .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@compression is not a named entity .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@alleviated is not a named entity .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@abnormality is not a named entity .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@craniocervical is not a named entity .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@production is not a named entity .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@in the is not a named entity .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@Temporary neurologic abnormalities is an Adverse-Effect named entity .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@methotrexate is a Drug named entity .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@osteogenic is not a named entity .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@23 is not a named entity .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@HD is not a named entity .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@Temporary is not a named entity .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@MTX is not a named entity .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@HD - MTX is not a named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@HD - MTX is a Drug named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@dysarthria is an Adverse-Effect named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@hemiparesis is an Adverse-Effect named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@altered consciousness is an Adverse-Effect named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@consciousness is not a named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@rescue is not a named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@MTX is not a named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@altered is not a named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@leucovorin is not a named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@alternative is not a named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@HD is not a named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@sequential is not a named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@gm is not a named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@including alternative is not a named entity .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@altered consciousness 5 is not a named entity .
Transient neurological disturbances induced by the chemotherapy of high - dose methotrexate for osteogenic sarcoma .@_@methotrexate is a Drug named entity .
Transient neurological disturbances induced by the chemotherapy of high - dose methotrexate for osteogenic sarcoma .@_@Transient neurological disturbances is an Adverse-Effect named entity .
Transient neurological disturbances induced by the chemotherapy of high - dose methotrexate for osteogenic sarcoma .@_@osteogenic is not a named entity .
Transient neurological disturbances induced by the chemotherapy of high - dose methotrexate for osteogenic sarcoma .@_@neurological disturbances induced is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@submucosal fibrosis of the transverse colon is an Adverse-Effect named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@stricture of the hepatic flexure region with associated narrowing is an Adverse-Effect named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@high - lipase pancreatin is a Drug named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@narrowing is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@pancreatin is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@CF is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@lipase is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@submucosal is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@stricture is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@flexure is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@transverse is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@colon is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@5-year is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@region is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@old boy with CF who had a stricture of is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@old boy with CF is not a named entity .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@the hepatic flexure region with associated is not a named entity .
Acute pancreatitis associated with danazol treatment for endometriosis .@_@danazol is a Drug named entity .
Acute pancreatitis associated with danazol treatment for endometriosis .@_@Acute pancreatitis is an Adverse-Effect named entity .
Acute pancreatitis associated with danazol treatment for endometriosis .@_@endometriosis is not a named entity .
Acute pancreatitis associated with danazol treatment for endometriosis .@_@pancreatitis associated is not a named entity .
Additionally , danazol produces hepatocellular damage in approximately 10 % of women .@_@danazol is a Drug named entity .
Additionally , danazol produces hepatocellular damage in approximately 10 % of women .@_@hepatocellular damage is an Adverse-Effect named entity .
Additionally , danazol produces hepatocellular damage in approximately 10 % of women .@_@Additionally is not a named entity .
Additionally , danazol produces hepatocellular damage in approximately 10 % of women .@_@produces is not a named entity .
Additionally , danazol produces hepatocellular damage in approximately 10 % of women .@_@of women is not a named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@Hypo - oestrogenic and anabolic / androgenic side - effects is an Adverse-Effect named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@danazol is a Drug named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@oestrogenic is not a named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@Hypo is not a named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@anabolic is not a named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@50 is not a named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@them is not a named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@> is not a named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@androgenic is not a named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@endometriosis is not a named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@gynaecologist is not a named entity .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@of danazol are well known by the gynaecologist and some is not a named entity .
The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis .@_@acute pancreatitis is an Adverse-Effect named entity .
The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis .@_@danazol is a Drug named entity .
The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis .@_@endometriosis is not a named entity .
The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis .@_@of acute is not a named entity .
Acyclovir neurotoxicity : clinical experience and review of the literature .@_@neurotoxicity is an Adverse-Effect named entity .
Acyclovir neurotoxicity : clinical experience and review of the literature .@_@Acyclovir is a Drug named entity .
Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .@_@neurologic symptoms is an Adverse-Effect named entity .
Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .@_@Acyclovir is a Drug named entity .
Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .@_@resemble is not a named entity .
Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .@_@extension is not a named entity .
Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .@_@produces is not a named entity .
Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .@_@viral is not a named entity .
Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .@_@symptoms that is not a named entity .
Systemic disease , most commonly renal dysfunction , preceded all 30 reported cases of acyclovir neurotoxicity .@_@neurotoxicity is an Adverse-Effect named entity .
Systemic disease , most commonly renal dysfunction , preceded all 30 reported cases of acyclovir neurotoxicity .@_@acyclovir is a Drug named entity .
Systemic disease , most commonly renal dysfunction , preceded all 30 reported cases of acyclovir neurotoxicity .@_@commonly is not a named entity .
Systemic disease , most commonly renal dysfunction , preceded all 30 reported cases of acyclovir neurotoxicity .@_@Systemic is not a named entity .
Systemic disease , most commonly renal dysfunction , preceded all 30 reported cases of acyclovir neurotoxicity .@_@preceded is not a named entity .
We discuss our observations in the cases of two patients with acyclovir neurotoxicity and review the findings of all previous reports in the English language literature .@_@neurotoxicity is an Adverse-Effect named entity .
We discuss our observations in the cases of two patients with acyclovir neurotoxicity and review the findings of all previous reports in the English language literature .@_@acyclovir is a Drug named entity .
We discuss our observations in the cases of two patients with acyclovir neurotoxicity and review the findings of all previous reports in the English language literature .@_@observations is not a named entity .
We discuss our observations in the cases of two patients with acyclovir neurotoxicity and review the findings of all previous reports in the English language literature .@_@language is not a named entity .
We discuss our observations in the cases of two patients with acyclovir neurotoxicity and review the findings of all previous reports in the English language literature .@_@English is not a named entity .
Response of a promethazine - induced coma to flumazenil .@_@promethazine is a Drug named entity .
Response of a promethazine - induced coma to flumazenil .@_@coma is an Adverse-Effect named entity .
Response of a promethazine - induced coma to flumazenil .@_@flumazenil is not a named entity .
Response of a promethazine - induced coma to flumazenil .@_@Response is not a named entity .
We report the first case of a patient in a promethazine - induced coma responding to treatment with flumazenil .@_@coma is an Adverse-Effect named entity .
We report the first case of a patient in a promethazine - induced coma responding to treatment with flumazenil .@_@promethazine is a Drug named entity .
We report the first case of a patient in a promethazine - induced coma responding to treatment with flumazenil .@_@responding is not a named entity .
We report the first case of a patient in a promethazine - induced coma responding to treatment with flumazenil .@_@flumazenil is not a named entity .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@neurotoxicity is an Adverse-Effect named entity .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@metronidazole is a Drug named entity .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@Amebic abscess of the spleen is an Adverse-Effect named entity .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@abscess is not a named entity .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@Amebic is not a named entity .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@spleen is not a named entity .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@induced neurotoxicity : case report is not a named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@liver abscess is an Adverse-Effect named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@splenic abscess is an Adverse-Effect named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@ataxia is an Adverse-Effect named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@tinnitus is an Adverse-Effect named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@reversible deafness is an Adverse-Effect named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@metronidazole is a Drug named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@splenic is not a named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@abscess is not a named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@relapsed is not a named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@deafness is not a named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@21 is not a named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@Entamoeba is not a named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@histolytica is not a named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@14 is not a named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@by reversible is not a named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@Entamoeba histolytica is not a named entity .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@metronidazole therapy is not a named entity .
Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .@_@Actinomycin D is a Drug named entity .
Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .@_@hepatic veno - occlusive disease is an Adverse-Effect named entity .
Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .@_@Actinomycin is not a named entity .
Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .@_@veno is not a named entity .
Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .@_@occlusive is not a named entity .
Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .@_@disease -- a report of is not a named entity .
Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .@_@- occlusive is not a named entity .
There are now reports of liver failure following treatment of childhood cancers with AMD .@_@AMD is a Drug named entity .
There are now reports of liver failure following treatment of childhood cancers with AMD .@_@liver failure is an Adverse-Effect named entity .
There are now reports of liver failure following treatment of childhood cancers with AMD .@_@cancers is not a named entity .
There are now reports of liver failure following treatment of childhood cancers with AMD .@_@now is not a named entity .
There are now reports of liver failure following treatment of childhood cancers with AMD .@_@childhood is not a named entity .
There are now reports of liver failure following treatment of childhood cancers with AMD .@_@of childhood is not a named entity .
Phenylpropanolamine - induced psychosis .@_@Phenylpropanolamine is a Drug named entity .
Phenylpropanolamine - induced psychosis .@_@psychosis is an Adverse-Effect named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@paranoid psychosis is an Adverse-Effect named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@PPA is a Drug named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@psychiatric adverse effects is an Adverse-Effect named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@decongestant is not a named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@guidelines is not a named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@recommended is not a named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@psychosis is not a named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@cae is not a named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@psychiatric is not a named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@paranoid is not a named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@summarize is not a named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@stated is not a named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@be within is not a named entity .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@effects to PPA is not a named entity .
CONCLUSIONS : Although budesonide may be beneficial because of its anti - inflammatory effects , clinicians should be alert to its potential for causing contact dermatitis .@_@contact dermatitis is an Adverse-Effect named entity .
CONCLUSIONS : Although budesonide may be beneficial because of its anti - inflammatory effects , clinicians should be alert to its potential for causing contact dermatitis .@_@budesonide is a Drug named entity .
CONCLUSIONS : Although budesonide may be beneficial because of its anti - inflammatory effects , clinicians should be alert to its potential for causing contact dermatitis .@_@beneficial is not a named entity .
CONCLUSIONS : Although budesonide may be beneficial because of its anti - inflammatory effects , clinicians should be alert to its potential for causing contact dermatitis .@_@alert is not a named entity .
CONCLUSIONS : Although budesonide may be beneficial because of its anti - inflammatory effects , clinicians should be alert to its potential for causing contact dermatitis .@_@causing is not a named entity .
CONCLUSIONS : Although budesonide may be beneficial because of its anti - inflammatory effects , clinicians should be alert to its potential for causing contact dermatitis .@_@budesonide may is not a named entity .
Contact dermatitis due to budesonide : report of five cases and review of the Japanese literature .@_@budesonide is a Drug named entity .
Contact dermatitis due to budesonide : report of five cases and review of the Japanese literature .@_@Contact dermatitis is an Adverse-Effect named entity .
Contact dermatitis due to budesonide : report of five cases and review of the Japanese literature .@_@Japanese is not a named entity .
Contact dermatitis due to budesonide : report of five cases and review of the Japanese literature .@_@Contact is not a named entity .
Contact dermatitis due to budesonide : report of five cases and review of the Japanese literature .@_@of five is not a named entity .
METHODS : Five cases of contact dermatitis due to budesonide , a nonhalogenated steroid , are described .@_@contact dermatitis is an Adverse-Effect named entity .
METHODS : Five cases of contact dermatitis due to budesonide , a nonhalogenated steroid , are described .@_@budesonide is a Drug named entity .
METHODS : Five cases of contact dermatitis due to budesonide , a nonhalogenated steroid , are described .@_@nonhalogenated is not a named entity .
METHODS : Five cases of contact dermatitis due to budesonide , a nonhalogenated steroid , are described .@_@Five is not a named entity .
METHODS : Five cases of contact dermatitis due to budesonide , a nonhalogenated steroid , are described .@_@nonhalogenated steroid is not a named entity .
RESULTS : Budesonide use can cause contact dermatitis .@_@Budesonide is a Drug named entity .
RESULTS : Budesonide use can cause contact dermatitis .@_@contact dermatitis is an Adverse-Effect named entity .
RESULTS : Budesonide use can cause contact dermatitis .@_@cause contact is not a named entity .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@methemoglobinemia is an Adverse-Effect named entity .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@methyl nitrite is a Drug named entity .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@nitrites is not a named entity .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@methyl is not a named entity .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@phenylpropanolamine is not a named entity .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@occupational is not a named entity .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@production is not a named entity .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@nitrite is not a named entity .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@be a is not a named entity .
Methemoglobinemia : an occupational hazard of phenylpropanolamine production .@_@Methemoglobinemia is an Adverse-Effect named entity .
Methemoglobinemia : an occupational hazard of phenylpropanolamine production .@_@phenylpropanolamine is a Drug named entity .
Methemoglobinemia : an occupational hazard of phenylpropanolamine production .@_@occupational is not a named entity .
Methemoglobinemia : an occupational hazard of phenylpropanolamine production .@_@production is not a named entity .
Methemoglobinemia : an occupational hazard of phenylpropanolamine production .@_@hazard is not a named entity .
During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .@_@IDDM is an Adverse-Effect named entity .
During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .@_@IFN is a Drug named entity .
During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .@_@diseases is not a named entity .
During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .@_@observe is not a named entity .
During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .@_@During is not a named entity .
During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .@_@carefully is not a named entity .
During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .@_@consider is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@severe ketonuria is an Adverse-Effect named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@moderate hyperglycemia is an Adverse-Effect named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@IFN is a Drug named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@acutely is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@28 is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@units is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@hyperglycemia is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@Four is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@antibody is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@islet is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@beginning is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@then is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@ketonuria is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@then 28 is not a named entity .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@and severe is not a named entity .
Occurrence of IDDM during interferon therapy for chronic viral hepatitis .@_@interferon is a Drug named entity .
Occurrence of IDDM during interferon therapy for chronic viral hepatitis .@_@IDDM is an Adverse-Effect named entity .
Occurrence of IDDM during interferon therapy for chronic viral hepatitis .@_@Occurrence is not a named entity .
We report a case of IDDM which occurred during interferon therapy for chronic hepatitis .@_@interferon is a Drug named entity .
We report a case of IDDM which occurred during interferon therapy for chronic hepatitis .@_@IDDM is an Adverse-Effect named entity .
Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .@_@carbamazepine is a Drug named entity .
Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .@_@hypersensitivity syndrome is an Adverse-Effect named entity .
Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .@_@Four is not a named entity .
Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .@_@antiepileptic is not a named entity .
Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .@_@AED is not a named entity .
Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .@_@are reported is not a named entity .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@seizures is an Adverse-Effect named entity .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@Recurrent hypotension is an Adverse-Effect named entity .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@nortriptyline is a Drug named entity .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@Recurrent is not a named entity .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@in nortriptyline is not a named entity .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@accelerate HIV disease is an Adverse-Effect named entity .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@MTX is a Drug named entity .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@methotrexate is a Drug named entity .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@accelerate is not a named entity .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@basis is not a named entity .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@contraindicated is not a named entity .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@opportunistic is not a named entity .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@potentiate is not a named entity .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@on the basis is not a named entity .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@increase of INR is an Adverse-Effect named entity .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@warfarin is a Drug named entity .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@5-FU is a Drug named entity .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@levamisole is a Drug named entity .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@adding is not a named entity .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@INR is not a named entity .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@alone is not a named entity .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@INR in an is not a named entity .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@increase in INR is an Adverse-Effect named entity .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@5-FU is a Drug named entity .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@warfarin is a Drug named entity .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@half is not a named entity .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@INR is not a named entity .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@prolongation is not a named entity .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@concurrent is not a named entity .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@INR have been is not a named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@ductopenia is an Adverse-Effect named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@vanishing bile duct syndrome is an Adverse-Effect named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@trimethoprim - sulfamethoxazole is a Drug named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@clindamycin is a Drug named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@Cholestatic liver disease is an Adverse-Effect named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@duct is not a named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@Cholestatic is not a named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@sulfamethoxazole is not a named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@vanishing is not a named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@trimethoprim is not a named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@- sulfamethoxazole . is not a named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@with ductopenia ( is not a named entity .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@of clindamycin and trimethoprim is not a named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@clindamycin is a Drug named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@ductopenia is an Adverse-Effect named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@portal inflammation is an Adverse-Effect named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct paucity is an Adverse-Effect named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct injury is an Adverse-Effect named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@marked cholestasis is an Adverse-Effect named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@cholestasis is not a named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@portal is not a named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@inflammation is not a named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@duct is not a named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@paucity is not a named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@biopsy findings of is not a named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@duct paucity ( is not a named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct is not a named entity .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@findings of is not a named entity .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@duct paucity is an Adverse-Effect named entity .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@cholestasis is an Adverse-Effect named entity .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@trimethoprim - sulfamethoxazole is a Drug named entity .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@paucity is not a named entity .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@sulfamethoxazole is not a named entity .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@trimethoprim is not a named entity .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@cholestasis after receiving is not a named entity .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@trimethoprim - is not a named entity .
This is the first description , to our knowledge , of ductopenia apparently caused by clindamycin .@_@clindamycin is a Drug named entity .
This is the first description , to our knowledge , of ductopenia apparently caused by clindamycin .@_@ductopenia is an Adverse-Effect named entity .
This is the first description , to our knowledge , of ductopenia apparently caused by clindamycin .@_@description is not a named entity .
This is the first description , to our knowledge , of ductopenia apparently caused by clindamycin .@_@apparently is not a named entity .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@duct paucity is an Adverse-Effect named entity .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@ampicillin is a Drug named entity .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@cholestatic hepatitis is an Adverse-Effect named entity .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@cholestasis is an Adverse-Effect named entity .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@cholestatic is not a named entity .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@paucity is not a named entity .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@rebiopsy is not a named entity .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@with cholestasis is not a named entity .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@paucity on is not a named entity .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@isoniazid is a Drug named entity .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@vision loss is an Adverse-Effect named entity .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@ethambutol is a Drug named entity .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@dramatic is not a named entity .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@9-month is not a named entity .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@permanent is not a named entity .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@A patient is not a named entity .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@development of visually related side effects is an Adverse-Effect named entity .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@isoniazid is a Drug named entity .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@Ethambutol is a Drug named entity .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@lesser is not a named entity .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@extent is not a named entity .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@visually is not a named entity .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@implicated is not a named entity .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@the development of visually related side is not a named entity .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@ocular toxicity is an Adverse-Effect named entity .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@ethambutol is a Drug named entity .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@documentation is not a named entity .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@pronounced is not a named entity .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@safe is not a named entity .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@generally is not a named entity .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@dosages is not a named entity .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@ethambutol when is not a named entity .
Toxic optic neuropathy associated with ethambutol : implications for current therapy .@_@ethambutol is a Drug named entity .
Toxic optic neuropathy associated with ethambutol : implications for current therapy .@_@Toxic optic neuropathy is an Adverse-Effect named entity .
Toxic optic neuropathy associated with ethambutol : implications for current therapy .@_@current is not a named entity .
Toxic optic neuropathy associated with ethambutol : implications for current therapy .@_@implications is not a named entity .
Toxic optic neuropathy associated with ethambutol : implications for current therapy .@_@Toxic is not a named entity .
Toxic optic neuropathy associated with ethambutol : implications for current therapy .@_@current therapy . is not a named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@fetal damage is an Adverse-Effect named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@teratogenic is an Adverse-Effect named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@zidovudine is a Drug named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@fetotoxic is an Adverse-Effect named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@requires is not a named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@fetal is not a named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@Currently is not a named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@decision is not a named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@evaluation is not a named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@available is not a named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@measures is not a named entity .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@for its is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@fetal abnormality is an Adverse-Effect named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@first trimester abortions is an Adverse-Effect named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@zidovudine is a Drug named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@gestations is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@fetal is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@terminations is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@where is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@104 is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@abortions is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@series is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@inadvertent is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@88 is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@intentional is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@abnormality is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@progressed is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@differing is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@trimester is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@eight spontaneous is not a named entity .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@total of 88 is not a named entity .
Zidovudine use in pregnancy : a report on 104 cases and the occurrence of birth defects .@_@birth defects is an Adverse-Effect named entity .
Zidovudine use in pregnancy : a report on 104 cases and the occurrence of birth defects .@_@Zidovudine is a Drug named entity .
Zidovudine use in pregnancy : a report on 104 cases and the occurrence of birth defects .@_@birth is not a named entity .
Zidovudine use in pregnancy : a report on 104 cases and the occurrence of birth defects .@_@104 is not a named entity .
Zidovudine use in pregnancy : a report on 104 cases and the occurrence of birth defects .@_@a report is not a named entity .
Celiprolol pneumonitis .@_@pneumonitis is an Adverse-Effect named entity .
Celiprolol pneumonitis .@_@Celiprolol is a Drug named entity .
Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis , 10 weeks after drug readministration .@_@pneumonitis is an Adverse-Effect named entity .
Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis , 10 weeks after drug readministration .@_@celiprolol is a Drug named entity .
Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis , 10 weeks after drug readministration .@_@Inadvertent is not a named entity .
Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis , 10 weeks after drug readministration .@_@readministration is not a named entity .
We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .@_@hypersensitivity pneumonitis is an Adverse-Effect named entity .
We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .@_@celiprolol is a Drug named entity .
We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .@_@blocker is not a named entity .
We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .@_@a patient is not a named entity .
Ibopamine - induced reversible leukopenia during treatment for congestive heart failure .@_@Ibopamine is a Drug named entity .
Ibopamine - induced reversible leukopenia during treatment for congestive heart failure .@_@leukopenia is an Adverse-Effect named entity .
Ibopamine - induced reversible leukopenia during treatment for congestive heart failure .@_@congestive is not a named entity .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@ibopamine is a Drug named entity .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@Reversible leukopenia is an Adverse-Effect named entity .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@congestive is not a named entity .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@81-year is not a named entity .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@t.i.d is not a named entity .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@adjunctive is not a named entity .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@leukopenia is not a named entity .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@chronic congestive is not a named entity .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@Diphenylhydantoin is a Drug named entity .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@acute intermittent porphyria is an Adverse-Effect named entity .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@intermittent is not a named entity .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@parameters is not a named entity .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@apparently is not a named entity .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@affected is not a named entity .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@porphyria is not a named entity .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@adversely is not a named entity .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@biochemical is not a named entity .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@apparently adversely affected is not a named entity .
Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin .@_@porphyria is an Adverse-Effect named entity .
Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin .@_@diphenylhydantoin is a Drug named entity .
Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin .@_@improvement is not a named entity .
Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin .@_@Significant is not a named entity .
A 53-year - old male , without any prior history of psychosis , developed schizophrenia 4 days after starting low - dose bromocriptine therapy for a macroprolactinoma .@_@schizophrenia is an Adverse-Effect named entity .
A 53-year - old male , without any prior history of psychosis , developed schizophrenia 4 days after starting low - dose bromocriptine therapy for a macroprolactinoma .@_@bromocriptine is a Drug named entity .
A 53-year - old male , without any prior history of psychosis , developed schizophrenia 4 days after starting low - dose bromocriptine therapy for a macroprolactinoma .@_@53-year is not a named entity .
A 53-year - old male , without any prior history of psychosis , developed schizophrenia 4 days after starting low - dose bromocriptine therapy for a macroprolactinoma .@_@macroprolactinoma is not a named entity .
A 53-year - old male , without any prior history of psychosis , developed schizophrenia 4 days after starting low - dose bromocriptine therapy for a macroprolactinoma .@_@psychosis is not a named entity .
Bromocriptine - induced schizophrenia .@_@Bromocriptine is a Drug named entity .
Bromocriptine - induced schizophrenia .@_@schizophrenia is an Adverse-Effect named entity .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@Concurrent acute megaloblastic anaemia is an Adverse-Effect named entity .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@methotrexate is a Drug named entity .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@pneumonitis is an Adverse-Effect named entity .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@anaemia is not a named entity .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@megaloblastic is not a named entity .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@Concurrent is not a named entity .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@- effect of low is not a named entity .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@pneumonitis is an Adverse-Effect named entity .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@methotrexate is a Drug named entity .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@acute megaloblastic anaemia is an Adverse-Effect named entity .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@megaloblastic is not a named entity .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@simultaneous is not a named entity .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@anaemia is not a named entity .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@anaemia and a is not a named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@respiratory distress syndrome is an Adverse-Effect named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@Levemepromazine is a Drug named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@methotrimeprazine meleate is a Drug named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@11-year is not a named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@intensive is not a named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@meleate is not a named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@phenothiazine is not a named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@distress is not a named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@unit is not a named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@relatively is not a named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@methotrimeprazine is not a named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@11-year - old is not a named entity .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@from respiratory is not a named entity .
The association of phenothiazine overdose and respiratory distress syndrome merits consideration .@_@phenothiazine is a Drug named entity .
The association of phenothiazine overdose and respiratory distress syndrome merits consideration .@_@respiratory distress syndrome is an Adverse-Effect named entity .
The association of phenothiazine overdose and respiratory distress syndrome merits consideration .@_@consideration is not a named entity .
The association of phenothiazine overdose and respiratory distress syndrome merits consideration .@_@merits is not a named entity .
The association of phenothiazine overdose and respiratory distress syndrome merits consideration .@_@syndrome merits consideration is not a named entity .
In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .@_@dyskinesias is an Adverse-Effect named entity .
In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .@_@apomorphine is a Drug named entity .
In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .@_@afternoon is not a named entity .
In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .@_@remained is not a named entity .
In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .@_@morning is not a named entity .
In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .@_@intensity is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@levo - dopa is a Drug named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@diphasic dyskinesias is an Adverse-Effect named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@movements is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@dyskinesias is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@reduce is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@duration is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@levo is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@dopa is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@diphasic is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@parkinsonian is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@observations is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@apomorphine is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@We report is not a named entity .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@of parkinsonian patients is not a named entity .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@severe lactate acidosis is an Adverse-Effect named entity .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@didanosine is a Drug named entity .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@Fulminant hepatitis is an Adverse-Effect named entity .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@lactate is not a named entity .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@Fulminant is not a named entity .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@in HIV is not a named entity .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@- infected patients is not a named entity .
This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients .@_@fulminant hepatitis is an Adverse-Effect named entity .
This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients .@_@ddI is a Drug named entity .
This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients .@_@suspect is not a named entity .
This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients .@_@us is not a named entity .
This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients .@_@prompted is not a named entity .
This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients .@_@hepatitis in is not a named entity .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@fulminant hepatic failure is an Adverse-Effect named entity .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@didanosine is a Drug named entity .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@ddI is a Drug named entity .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@HIV-1-infected is not a named entity .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@HIV-1-infected patients treated is not a named entity .
Generalized argyria after habitual use of AgNO3 .@_@Generalized argyria is an Adverse-Effect named entity .
Generalized argyria after habitual use of AgNO3 .@_@AgNO3 is a Drug named entity .
Generalized argyria after habitual use of AgNO3 .@_@argyria is not a named entity .
Generalized argyria after habitual use of AgNO3 .@_@Generalized is not a named entity .
Generalized argyria after habitual use of AgNO3 .@_@habitual is not a named entity .
Generalized argyria after habitual use of AgNO3 .@_@after habitual is not a named entity .
A case of fluoxetine induced seizures , in a person with Down syndrome , is described .@_@fluoxetine is a Drug named entity .
A case of fluoxetine induced seizures , in a person with Down syndrome , is described .@_@seizures is an Adverse-Effect named entity .
A case of fluoxetine induced seizures , in a person with Down syndrome , is described .@_@person is not a named entity .
A case of fluoxetine induced seizures , in a person with Down syndrome , is described .@_@Down is not a named entity .
Seizures associated with fluoxetine therapy are uncommon .@_@Seizures is an Adverse-Effect named entity .
Seizures associated with fluoxetine therapy are uncommon .@_@fluoxetine is a Drug named entity .
Seizures associated with fluoxetine therapy .@_@fluoxetine is a Drug named entity .
Seizures associated with fluoxetine therapy .@_@Seizures is an Adverse-Effect named entity .
Although fluoxetine - induced headache occurred in one patient , the other five reported no side effects at the doses used .@_@fluoxetine is a Drug named entity .
Although fluoxetine - induced headache occurred in one patient , the other five reported no side effects at the doses used .@_@headache is an Adverse-Effect named entity .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@psoriasiform eruptions is an Adverse-Effect named entity .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@carbamazepine is a Drug named entity .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@Sodium valproate is a Drug named entity .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@growing is not a named entity .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@antiepileptic is not a named entity .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@valproate is not a named entity .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@Sodium is not a named entity .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@relatively is not a named entity .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@psoriasiform is not a named entity .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@list of is not a named entity .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@that produce is not a named entity .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@psoriasiform eruption is an Adverse-Effect named entity .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@sodium valproate is a Drug named entity .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@carbamazepine is a Drug named entity .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@valproate is not a named entity .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@antiepileptic is not a named entity .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@apparently is not a named entity .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@psoriasiform is not a named entity .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@findings from is not a named entity .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@carbamazepine . is not a named entity .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@BCNU is a Drug named entity .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@carmustine is a Drug named entity .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@Severe diffuse interstitial pneumonitis is an Adverse-Effect named entity .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@induced by carmustine ( is not a named entity .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@BCNU is a Drug named entity .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@carmustine is a Drug named entity .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@fatal case of acute interstitial pneumonitis is an Adverse-Effect named entity .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@( BCNU ) for a brain is not a named entity .
A 78-year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .@_@procainamide is a Drug named entity .
A 78-year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .@_@shocks is an Adverse-Effect named entity .
A 78-year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .@_@frequent is not a named entity .
A 78-year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .@_@transvenous is not a named entity .
A 78-year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .@_@78-year is not a named entity .
A 78-year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .@_@cardioverter is not a named entity .
A 78-year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .@_@defibrillator is not a named entity .
Electrical proarrhythmia with procainamide : a new ICD - drug interaction .@_@Electrical proarrhythmia is an Adverse-Effect named entity .
Electrical proarrhythmia with procainamide : a new ICD - drug interaction .@_@procainamide is a Drug named entity .
Electrical proarrhythmia with procainamide : a new ICD - drug interaction .@_@Electrical is not a named entity .
Electrical proarrhythmia with procainamide : a new ICD - drug interaction .@_@ICD is not a named entity .
Electrical proarrhythmia with procainamide : a new ICD - drug interaction .@_@proarrhythmia is not a named entity .
Electrical proarrhythmia with procainamide : a new ICD - drug interaction .@_@interaction . is not a named entity .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@procainamide is a Drug named entity .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@electrophysiologic effect is an Adverse-Effect named entity .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@electrophysiologic is not a named entity .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@idiosyncratic is not a named entity .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@reproduce is not a named entity .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@either is not a named entity .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@mexiletine is not a named entity .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@observation is not a named entity .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@unreported is not a named entity .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@disopyramide is not a named entity .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@or idiosyncratic is not a named entity .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@valproic acid is a Drug named entity .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@altered mental status is an Adverse-Effect named entity .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@ammonia is not a named entity .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@altered is not a named entity .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@Based is not a named entity .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@mental is not a named entity .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@appear is not a named entity .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@ED is not a named entity .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@indicated in all is not a named entity .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@in all is not a named entity .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@Hyperammonemia is an Adverse-Effect named entity .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@lethargy is an Adverse-Effect named entity .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@valproic acid is a Drug named entity .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@overlooked is not a named entity .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@presents is not a named entity .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@emergency is not a named entity .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@department is not a named entity .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@postictal is not a named entity .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@cause of is not a named entity .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@lethargy is an Adverse-Effect named entity .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@Hyperammonemia is an Adverse-Effect named entity .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@valproic acid is a Drug named entity .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@postictal is not a named entity .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@in a is not a named entity .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@valproic acid is a Drug named entity .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@lethargy is an Adverse-Effect named entity .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@hyperammonemia is an Adverse-Effect named entity .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@postictal is not a named entity .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@tests is not a named entity .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@otherwise is not a named entity .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@a postictal is not a named entity .
Central nervous system toxicity associated with meperidine use in hepatic disease .@_@meperidine is a Drug named entity .
Central nervous system toxicity associated with meperidine use in hepatic disease .@_@Central nervous system toxicity is an Adverse-Effect named entity .
Central nervous system toxicity associated with meperidine use in hepatic disease .@_@Central is not a named entity .
Central nervous system toxicity associated with meperidine use in hepatic disease .@_@associated with meperidine use is not a named entity .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@meperidine is a Drug named entity .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@accumulation of the parent drug is an Adverse-Effect named entity .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@CNS depressive effects is an Adverse-Effect named entity .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@accumulation is not a named entity .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@metabolism is not a named entity .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@depressive is not a named entity .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@parent is not a named entity .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@cirrhosis is not a named entity .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@In patients with cirrhosis , is not a named entity .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@cirrhosis , the is not a named entity .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@central nervous system ( CNS ) excitatory toxicities is an Adverse-Effect named entity .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@Meperidine is a Drug named entity .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@accumulation of the active metabolite normeperidine is an Adverse-Effect named entity .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@accumulation is not a named entity .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@normeperidine is not a named entity .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@excitatory is not a named entity .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@toxicities is not a named entity .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@metabolite is not a named entity .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@associated central nervous system ( CNS is not a named entity .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@Meperidine - associated central nervous system ( CNS is not a named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@status epilepticus is an Adverse-Effect named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@intracerebral hemorrhage is an Adverse-Effect named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@morphine is a Drug named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@respiratory failure is an Adverse-Effect named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@hypertension is an Adverse-Effect named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@intrathecally is not a named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@intracerebral is not a named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@accidental is not a named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@bolus is not a named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@450-mg is not a named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@an accidental is not a named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@hypertension , is not a named entity .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@She received is not a named entity .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@MMC is a Drug named entity .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@hemolytic - uremic syndrome is an Adverse-Effect named entity .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@Mitomycin C is a Drug named entity .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@HUS is an Adverse-Effect named entity .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@Mitomycin is not a named entity .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@alkylating is not a named entity .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@has been recently associated is not a named entity .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@alkylating agent is not a named entity .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@mitomycin C is a Drug named entity .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@hemolytic - uremic syndrome is an Adverse-Effect named entity .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@Pulmonary hemorrhage is an Adverse-Effect named entity .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@mitomycin is not a named entity .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@manifestation is not a named entity .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@of hemolytic - uremic is not a named entity .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@a clinical is not a named entity .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@syndrome associated is not a named entity .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@Pulmonary hemorrhage is an Adverse-Effect named entity .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@HUS is an Adverse-Effect named entity .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@MMC is a Drug named entity .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@feature is not a named entity .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@appear is not a named entity .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@hemorrhage is is not a named entity .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@HUS is an Adverse-Effect named entity .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@massive pulmonary bleeding is an Adverse-Effect named entity .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@MMC is a Drug named entity .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@describe two women is not a named entity .
Clonidine - induced bradycardia in patients with spinal cord injury .@_@bradycardia is an Adverse-Effect named entity .
Clonidine - induced bradycardia in patients with spinal cord injury .@_@Clonidine is a Drug named entity .
Clonidine - induced bradycardia in patients with spinal cord injury .@_@cord is not a named entity .
Clonidine - induced bradycardia in patients with spinal cord injury .@_@spinal is not a named entity .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@clonidine is a Drug named entity .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@bradycardia is an Adverse-Effect named entity .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@Possible is not a named entity .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@decreases is not a named entity .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@recommendations is not a named entity .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@spasticity is not a named entity .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@injured is not a named entity .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@spinal is not a named entity .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@cord is not a named entity .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@clonidine is a Drug named entity .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@hypotension is an Adverse-Effect named entity .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@dry mouth is an Adverse-Effect named entity .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@bradycardia is an Adverse-Effect named entity .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@constipation is an Adverse-Effect named entity .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@Though is not a named entity .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@mouth is not a named entity .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@dry is not a named entity .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@are well is not a named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@hyperkalaemia is an Adverse-Effect named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@increased urinary N - acetyl glucosaminase is an Adverse-Effect named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@elevation of serum creatinine and blood urea is an Adverse-Effect named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@one patient became unconscious is an Adverse-Effect named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@cotrimoxazole is a Drug named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@acetyl is not a named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@N is not a named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@glucosaminase is not a named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@unconscious is not a named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@urea is not a named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@creatinine is not a named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@, and increased urinary N - acetyl is not a named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@; one patient became unconscious . is not a named entity .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@elevation of serum creatinine is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@Hyperkalaemia is an Adverse-Effect named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@sulfamethoxazole - trimethoprim is a Drug named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@renal tubular dysfunction is an Adverse-Effect named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@co - trimoxazole is a Drug named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@malignancy is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@Japanese is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@lymphoid is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@trimoxazole is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@trimethoprim is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@tubular is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@carinii is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@sulfamethoxazole is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@Pneumocystis is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@co is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@, who developed is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@- trimoxazole ) is not a named entity .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@with lymphoid malignancy is not a named entity .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@sulfamethoxazole - trimethoprim is a Drug named entity .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@renal tubular dysfunction is an Adverse-Effect named entity .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@Hyperkalaemia is an Adverse-Effect named entity .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@malignancy is not a named entity .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@trimethoprim is not a named entity .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@Pneumocystis is not a named entity .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@carinii is not a named entity .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@lymphoid is not a named entity .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@sulfamethoxazole is not a named entity .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@with lymphoid malignancy is not a named entity .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@lymphoid malignancy . is not a named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@nitrous oxide is a Drug named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@subacute combined degeneration of the spinal cord is an Adverse-Effect named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@degeneration is not a named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@subacute is not a named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@unsuspected is not a named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@oxide is not a named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@B12 is not a named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@vitamin is not a named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@nitrous is not a named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@anesthesia is not a named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@spinal is not a named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@presented in which patients unsuspected of having is not a named entity .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@from the is not a named entity .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@Neurologic degeneration is an Adverse-Effect named entity .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@nitrous oxide is a Drug named entity .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@B12 is not a named entity .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@anesthesia is not a named entity .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@oxide is not a named entity .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@Neurologic is not a named entity .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@vitamin is not a named entity .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@nitrous is not a named entity .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@in patients is not a named entity .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@associated with is not a named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@neurologic deterioration is an Adverse-Effect named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@nitrous oxide is a Drug named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@exceedingly is not a named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@nitrous is not a named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@anesthesia is not a named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@B12 is not a named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@vitamin is not a named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@deterioration is not a named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@sensitive is not a named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@oxide is not a named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@vitamin B12 is not a named entity .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@Patients with is not a named entity .
BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .@_@sexual dysfunction is an Adverse-Effect named entity .
BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .@_@Fluoxetine is a Drug named entity .
BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .@_@reuptake is not a named entity .
BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .@_@minority is not a named entity .
BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .@_@highly is not a named entity .
BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .@_@sexual is not a named entity .
BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .@_@cause sexual is not a named entity .
Captopril - induced bone marrow suppression in two cardiac patients with trisomy 21 .@_@Captopril is a Drug named entity .
Captopril - induced bone marrow suppression in two cardiac patients with trisomy 21 .@_@bone marrow suppression is an Adverse-Effect named entity .
Captopril - induced bone marrow suppression in two cardiac patients with trisomy 21 .@_@suppression is not a named entity .
Captopril - induced bone marrow suppression in two cardiac patients with trisomy 21 .@_@trisomy is not a named entity .
Captopril - induced bone marrow suppression in two cardiac patients with trisomy 21 .@_@21 is not a named entity .
Captopril - induced bone marrow suppression in two cardiac patients with trisomy 21 .@_@trisomy 21 . is not a named entity .
Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor , captopril .@_@captopril is a Drug named entity .
Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor , captopril .@_@Neutropenia is an Adverse-Effect named entity .
Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor , captopril .@_@angiotensin is not a named entity .
Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor , captopril .@_@infrequent is not a named entity .
Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor , captopril .@_@ACE is not a named entity .
Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor , captopril .@_@converting is not a named entity .
We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21 .@_@captopril is a Drug named entity .
We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21 .@_@neutropenia is an Adverse-Effect named entity .
We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21 .@_@21 is not a named entity .
We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21 .@_@trisomy is not a named entity .
Can magnesium sulfate therapy impact lactogenesis ?@_@lactogenesis is an Adverse-Effect named entity .
Can magnesium sulfate therapy impact lactogenesis ?@_@magnesium sulfate is a Drug named entity .
Can magnesium sulfate therapy impact lactogenesis ?@_@Can is not a named entity .
Can magnesium sulfate therapy impact lactogenesis ?@_@impact is not a named entity .
Can magnesium sulfate therapy impact lactogenesis ?@_@magnesium is not a named entity .
Can magnesium sulfate therapy impact lactogenesis ?@_@sulfate is not a named entity .
Can magnesium sulfate therapy impact lactogenesis ?@_@lactogenesis ? is not a named entity .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@magnesium sulfate is a Drug named entity .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@impeded lactogenesis is an Adverse-Effect named entity .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@sulfate is not a named entity .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@delay is not a named entity .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@magnesium is not a named entity .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@lactogenesis is not a named entity .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@explanation is not a named entity .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@impeded is not a named entity .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@No is not a named entity .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@than the is not a named entity .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@found , is not a named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@flare - up is an Adverse-Effect named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@worsening pleuritis carcinomatosa is an Adverse-Effect named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@severe dyspnea is an Adverse-Effect named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@goserelin acetate is a Drug named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@goserelin is not a named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@pleuritis is not a named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@carcinomatosa is not a named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@dyspnea is not a named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@flare is not a named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@3.6 is not a named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@days after the is not a named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@after the is not a named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@considered as is not a named entity .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@pleuritis carcinomatosa , is not a named entity .
Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .@_@Imidazoline intoxication is an Adverse-Effect named entity .
Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .@_@Imidazoline is a Drug named entity .
Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .@_@frequent is not a named entity .
Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .@_@usage is not a named entity .
Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .@_@overdose or is not a named entity .
Imidazoline intoxication in children .@_@Imidazoline intoxication is an Adverse-Effect named entity .
Imidazoline intoxication in children .@_@Imidazoline is a Drug named entity .
Imidazoline intoxication in children .@_@in children is not a named entity .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@L - asparaginase is a Drug named entity .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@aphasia is an Adverse-Effect named entity .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@neuropsychological deficits is an Adverse-Effect named entity .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@Cerebrovascular complications is an Adverse-Effect named entity .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@Cerebrovascular is not a named entity .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@neuropsychological is not a named entity .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@deficits is not a named entity .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@of L - is not a named entity .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@children with is not a named entity .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@of L is not a named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@cerebral thrombosis is an Adverse-Effect named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@hemorrhage is an Adverse-Effect named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@L - asparaginase is a Drug named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@coagulation protein deficiencies is an Adverse-Effect named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@coagulation is not a named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@protein is not a named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@Children is not a named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@deficiencies is not a named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@ALL is not a named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@of coagulation is not a named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@lymphoblastic leukemia ( is not a named entity .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@, treated with is not a named entity .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@Myoclonus is an Adverse-Effect named entity .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@L - dopa is a Drug named entity .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@seizures is an Adverse-Effect named entity .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@VPA is not a named entity .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@valproate is not a named entity .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@dopa is not a named entity .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@and seizures disappeared is not a named entity .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@seizures is an Adverse-Effect named entity .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@levodopa is a Drug named entity .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@Myoclonus is an Adverse-Effect named entity .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@SEPs is not a named entity .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@confirmation is not a named entity .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@parkinsonism is not a named entity .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@L - dopa is a Drug named entity .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@generalized seizures is an Adverse-Effect named entity .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@Myoclonus is an Adverse-Effect named entity .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@enhanced is not a named entity .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@dopa is not a named entity .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@, developing is not a named entity .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@developing into generalized is not a named entity .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@myoclonus is an Adverse-Effect named entity .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@L - dopa is a Drug named entity .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@seizures is an Adverse-Effect named entity .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@parkinsonism is not a named entity .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@dopa is not a named entity .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@SEPs is not a named entity .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@of parkinsonism with is not a named entity .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@excessive maternal and physician anxiety is an Adverse-Effect named entity .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@acyclovir is a Drug named entity .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@physician is not a named entity .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@Unintended is not a named entity .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@excessive is not a named entity .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@anxiety is not a named entity .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@maternal is not a named entity .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@to acyclovir early in pregnancy is not a named entity .
A severe form of exophthalmos resulting from lithium therapy has not been described in the literature .@_@lithium is a Drug named entity .
A severe form of exophthalmos resulting from lithium therapy has not been described in the literature .@_@exophthalmos is an Adverse-Effect named entity .
A severe form of exophthalmos resulting from lithium therapy has not been described in the literature .@_@form is not a named entity .
Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria .@_@polyuria is an Adverse-Effect named entity .
Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria .@_@Lithium is a Drug named entity .
Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria .@_@intolerable is not a named entity .
Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria .@_@poor is not a named entity .
Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria .@_@compliance is not a named entity .
Regression of thyrotoxic ophthalmopathy following lithium withdrawal .@_@thyrotoxic ophthalmopathy is an Adverse-Effect named entity .
Regression of thyrotoxic ophthalmopathy following lithium withdrawal .@_@lithium is a Drug named entity .
Regression of thyrotoxic ophthalmopathy following lithium withdrawal .@_@thyrotoxic is not a named entity .
Regression of thyrotoxic ophthalmopathy following lithium withdrawal .@_@ophthalmopathy is not a named entity .
Regression of thyrotoxic ophthalmopathy following lithium withdrawal .@_@Regression is not a named entity .
Regression of thyrotoxic ophthalmopathy following lithium withdrawal .@_@following lithium is not a named entity .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@lithium is a Drug named entity .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@thyrotoxicosis is an Adverse-Effect named entity .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@severe exophthalmos is an Adverse-Effect named entity .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@exophthalmos is not a named entity .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@a bipolar is not a named entity .
The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium .@_@exophthalmos is an Adverse-Effect named entity .
The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium .@_@lithium is a Drug named entity .
The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium .@_@dramatically is not a named entity .
The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium .@_@72 is not a named entity .
Severe abdominal pain in low dosage clofazimine .@_@abdominal pain is an Adverse-Effect named entity .
Severe abdominal pain in low dosage clofazimine .@_@clofazimine is a Drug named entity .
Severe abdominal pain in low dosage clofazimine .@_@low dosage is not a named entity .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@clofazimine is a Drug named entity .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@abdominal pain is an Adverse-Effect named entity .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@leprosy is not a named entity .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@underwent is not a named entity .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@41 is not a named entity .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@yrs is not a named entity .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@laparotomy is not a named entity .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@yr is not a named entity .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@41 yr is not a named entity .
Amphotericin B overdose in pediatric patients with associated cardiac arrest .@_@cardiac arrest is an Adverse-Effect named entity .
Amphotericin B overdose in pediatric patients with associated cardiac arrest .@_@Amphotericin B is a Drug named entity .
Amphotericin B overdose in pediatric patients with associated cardiac arrest .@_@Amphotericin is not a named entity .
Amphotericin B overdose in pediatric patients with associated cardiac arrest .@_@arrest . is not a named entity .
Amphotericin B overdose in pediatric patients with associated cardiac arrest .@_@with associated is not a named entity .
CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .@_@fatal is an Adverse-Effect named entity .
CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .@_@Amphotericin B is a Drug named entity .
CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .@_@Amphotericin is not a named entity .
CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .@_@be fatal is not a named entity .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@mortality is an Adverse-Effect named entity .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@amphotericin B is a Drug named entity .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@cardiac arrhythmias is an Adverse-Effect named entity .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@Hydrocortisone is not a named entity .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@overdoses is not a named entity .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@arrhythmias is not a named entity .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@children receiving is not a named entity .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@arrhythmias in is not a named entity .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@amphotericin B is a Drug named entity .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@Cardiac complications is an Adverse-Effect named entity .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@Cardiac is not a named entity .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@INTERVENTIONS is not a named entity .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@AND is not a named entity .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@kg is not a named entity .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@d is not a named entity .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@4.6 is not a named entity .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@40.8 is not a named entity .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@mg / is not a named entity .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@who received is not a named entity .
OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .@_@amphotericin B is a Drug named entity .
OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .@_@cardiac complications is an Adverse-Effect named entity .
OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .@_@population is not a named entity .
OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .@_@a pediatric is not a named entity .
OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .@_@complications in is not a named entity .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@cyclosporine is a Drug named entity .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@prednisone is a Drug named entity .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@Hypertension is an Adverse-Effect named entity .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@immunosuppression is not a named entity .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@develops is not a named entity .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@Sudden death is an Adverse-Effect named entity .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@sweet spirits of nitre is a Drug named entity .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@spirits is not a named entity .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@nitre is not a named entity .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@sweet is not a named entity .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@methemoglobinemia is not a named entity .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@death is not a named entity .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@Sudden is not a named entity .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@methemoglobinemia after is not a named entity .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@methemoglobinemia after administration of is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@hypoxemia is an Adverse-Effect named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@sweet spirits of nitre is a Drug named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@died is an Adverse-Effect named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@acute methemoglobinemia is an Adverse-Effect named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol is a Drug named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@severe anoxic metabolic acidosis is an Adverse-Effect named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@consequences is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@blue is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@70 is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@methemoglobinemia is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@twin is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@reversed is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@sweet is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@nitre is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@CH3CH2ONO is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@anoxic is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@alcohol is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@ethyl is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@nitrite is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@Methylene is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@twins is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@spirits is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@administration of is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@alcohol ) was followed by acute methemoglobinemia and severe anoxic is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@of " sweet spirits is not a named entity .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@metabolic acidosis in infant is not a named entity .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@valproate is a Drug named entity .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@Hepatotoxic effects is an Adverse-Effect named entity .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@carnitine is a Drug named entity .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@Hepatotoxic is not a named entity .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@receiving valproate is not a named entity .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@fatal hepatotoxic effects is an Adverse-Effect named entity .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@valproic acid is a Drug named entity .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@prevent is not a named entity .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@hepatotoxic is not a named entity .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@supplementation is not a named entity .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@Carnitine is not a named entity .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@with valproic acid is not a named entity .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@has been is not a named entity .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@fatal is an Adverse-Effect named entity .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@valproate is a Drug named entity .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@hepatotoxic effects is an Adverse-Effect named entity .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@hepatotoxic is not a named entity .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@supplementation is not a named entity .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@We report is not a named entity .
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction .@_@cognitive dysfunction is an Adverse-Effect named entity .
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction .@_@IL-2 is a Drug named entity .
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction .@_@leptomeningeal is not a named entity .
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction .@_@cognitive is not a named entity .
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction .@_@40 is not a named entity .
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction .@_@intraventricular is not a named entity .
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction .@_@40 year is not a named entity .
Delayed neurotoxicity of intraventricular interleukin-2 : a case report .@_@neurotoxicity is an Adverse-Effect named entity .
Delayed neurotoxicity of intraventricular interleukin-2 : a case report .@_@interleukin-2 is a Drug named entity .
Delayed neurotoxicity of intraventricular interleukin-2 : a case report .@_@Delayed is not a named entity .
Delayed neurotoxicity of intraventricular interleukin-2 : a case report .@_@intraventricular is not a named entity .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@brain injury is an Adverse-Effect named entity .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@IL-2 is a Drug named entity .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@disability is an Adverse-Effect named entity .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@intraventricular is not a named entity .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@potential for is not a named entity .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@lithium is a Drug named entity .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@thyroid dysfunctions is an Adverse-Effect named entity .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@Kong is not a named entity .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@dysfunctions is not a named entity .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@Albeit is not a named entity .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@Chinese is not a named entity .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@Western is not a named entity .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@Hong is not a named entity .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@Chinese . is not a named entity .
Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .@_@lithium is a Drug named entity .
Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .@_@thyrotoxicosis is an Adverse-Effect named entity .
Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .@_@maintenance is not a named entity .
Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .@_@depressive is not a named entity .
Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .@_@thyroiditis is not a named entity .
Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .@_@manic is not a named entity .
Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .@_@Chinese is not a named entity .
Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .@_@transient thyrotoxicosis is an Adverse-Effect named entity .
Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .@_@Lithium is a Drug named entity .
Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .@_@thyroiditis is not a named entity .
Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .@_@Chinese is not a named entity .
Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .@_@thyrotoxicosis is not a named entity .
Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .@_@thyrotoxicosis in is not a named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@lithium is a Drug named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@toxic and immunomodulatory roles is an Adverse-Effect named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@roles is not a named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@involve is not a named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@aetiological is not a named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@genetic is not a named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@dietary is not a named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@They is not a named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@perhaps is not a named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@immunomodulatory is not a named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@seemed is not a named entity .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@seemed to involve multiple is not a named entity .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@fatal complication is an Adverse-Effect named entity .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@retinoic acid is a Drug named entity .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@retinoic acid syndrome is an Adverse-Effect named entity .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@majority is not a named entity .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@retinoic is not a named entity .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@tolerated is not a named entity .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@kind is not a named entity .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@tolerated by is not a named entity .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@" the is not a named entity .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@is well tolerated is not a named entity .
CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .@_@foscarnet is a Drug named entity .
CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .@_@electrolyte disorders is an Adverse-Effect named entity .
CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .@_@contributed is not a named entity .
CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .@_@symptomatology is not a named entity .
CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .@_@electrolyte is not a named entity .
CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .@_@: It is not a named entity .
DISCUSSION : Electrolyte disorders associated with foscarnet are reviewed .@_@Electrolyte disorders is an Adverse-Effect named entity .
DISCUSSION : Electrolyte disorders associated with foscarnet are reviewed .@_@foscarnet is a Drug named entity .
DISCUSSION : Electrolyte disorders associated with foscarnet are reviewed .@_@Electrolyte is not a named entity .
DISCUSSION : Electrolyte disorders associated with foscarnet are reviewed .@_@associated with is not a named entity .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@Foscarnet is a Drug named entity .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@electrolyte disorders is an Adverse-Effect named entity .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@severe hypomagnesemia is an Adverse-Effect named entity .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@electrolyte is not a named entity .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@hypomagnesemia is not a named entity .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@and other is not a named entity .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@induced severe is not a named entity .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@severe hypomagnesemia is an Adverse-Effect named entity .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@foscarnet is a Drug named entity .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@electrolyte disorders is an Adverse-Effect named entity .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@electrolyte is not a named entity .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@hypomagnesemia is not a named entity .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@report a is not a named entity .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@OBJECTIVE : is not a named entity .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@anxiety is an Adverse-Effect named entity .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@foscarnet is a Drug named entity .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@muscle twitches is an Adverse-Effect named entity .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@tremulousness is an Adverse-Effect named entity .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@twitches is not a named entity .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@17 is not a named entity .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@therapy . is not a named entity .
Interference with the cortisol axis by the microtubule antagonist , CPH82 .@_@Interference with the cortisol axis is an Adverse-Effect named entity .
Interference with the cortisol axis by the microtubule antagonist , CPH82 .@_@CPH82 is a Drug named entity .
Interference with the cortisol axis by the microtubule antagonist , CPH82 .@_@microtubule is not a named entity .
Interference with the cortisol axis by the microtubule antagonist , CPH82 .@_@cortisol is not a named entity .
Interference with the cortisol axis by the microtubule antagonist , CPH82 .@_@axis is not a named entity .
Interference with the cortisol axis by the microtubule antagonist , CPH82 .@_@Interference is not a named entity .
Interference with the cortisol axis by the microtubule antagonist , CPH82 .@_@with the cortisol axis by is not a named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@suppression of the endogeneous production of ACTH and cortisol is an Adverse-Effect named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@hypercortisolism is an Adverse-Effect named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@CPH82 is a Drug named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@cortisol is not a named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@suppression is not a named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@endogeneous is not a named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@paradoxical is not a named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@ACTH is not a named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@clearly is not a named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@demonstrate is not a named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@picture is not a named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@production is not a named entity .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@endogeneous production of ACTH and cortisol with a concomitant is not a named entity .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@CBZ is a Drug named entity .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@tics is an Adverse-Effect named entity .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@movement disorders is an Adverse-Effect named entity .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@carbamazepine is a Drug named entity .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@Tourette is not a named entity .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@variety is not a named entity .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@infrequently is not a named entity .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@movement is not a named entity .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@disorders . is not a named entity .
Carbamazepine - induced tics .@_@Carbamazepine is a Drug named entity .
Carbamazepine - induced tics .@_@tics is an Adverse-Effect named entity .
In the third child , the tics ceased after CBZ discontinuation .@_@tics is an Adverse-Effect named entity .
In the third child , the tics ceased after CBZ discontinuation .@_@CBZ is a Drug named entity .
In the third child , the tics ceased after CBZ discontinuation .@_@ceased is not a named entity .
These cases demonstrate that CBZ can induce simple motor tics in children .@_@motor tics is an Adverse-Effect named entity .
These cases demonstrate that CBZ can induce simple motor tics in children .@_@CBZ is a Drug named entity .
These cases demonstrate that CBZ can induce simple motor tics in children .@_@simple is not a named entity .
These cases demonstrate that CBZ can induce simple motor tics in children .@_@motor is not a named entity .
These cases demonstrate that CBZ can induce simple motor tics in children .@_@demonstrate is not a named entity .
These cases demonstrate that CBZ can induce simple motor tics in children .@_@tics is not a named entity .
These cases demonstrate that CBZ can induce simple motor tics in children .@_@cases demonstrate is not a named entity .
We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .@_@CBZ is a Drug named entity .
We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .@_@facial motor tics is an Adverse-Effect named entity .
We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .@_@tics is not a named entity .
We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .@_@partial is not a named entity .
We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .@_@motor is not a named entity .
We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .@_@facial is not a named entity .
We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .@_@partial seizures . is not a named entity .
Acyclovir - induced neurotoxicity : concentration - side effect relationship in acyclovir overdose .@_@Acyclovir is a Drug named entity .
Acyclovir - induced neurotoxicity : concentration - side effect relationship in acyclovir overdose .@_@neurotoxicity is an Adverse-Effect named entity .
Acyclovir - induced neurotoxicity : concentration - side effect relationship in acyclovir overdose .@_@acyclovir is not a named entity .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@neurotoxicity is an Adverse-Effect named entity .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@acyclovir is a Drug named entity .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@wide is not a named entity .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@observation is not a named entity .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@explain is not a named entity .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@delay is not a named entity .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@range is not a named entity .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@peak is not a named entity .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@coma is an Adverse-Effect named entity .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@nonoliguric renal failure is an Adverse-Effect named entity .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@acyclovir is a Drug named entity .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@nonoliguric is not a named entity .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@Repeated is not a named entity .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@drawn is not a named entity .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@samples is not a named entity .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@drawn in a is not a named entity .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@neurotoxicity is an Adverse-Effect named entity .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@acyclovir is a Drug named entity .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@central nervous system side effects is an Adverse-Effect named entity .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@available is not a named entity .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@information is not a named entity .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@investigate is not a named entity .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@summarize is not a named entity .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@concentration - side effect relationship is not a named entity .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@tryptophan is a Drug named entity .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@eosinophilia myalgia syndrome is an Adverse-Effect named entity .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@support is not a named entity .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@solutions is not a named entity .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@autologous is not a named entity .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@biphenotypic is not a named entity .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@16-year is not a named entity .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@nutritional is not a named entity .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@myalgia is not a named entity .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@parenteral is not a named entity .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@and also after is not a named entity .
Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .@_@Fatal eosinophilia myalgia syndrome is an Adverse-Effect named entity .
Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .@_@tryptophan is a Drug named entity .
Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .@_@myalgia is not a named entity .
Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .@_@solution is not a named entity .
Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .@_@nutrition is not a named entity .
Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .@_@parenteral is not a named entity .
Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .@_@nutrition with a solution is not a named entity .
Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .@_@eosinophilia myalgia syndrome is an Adverse-Effect named entity .
Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .@_@tryptophan is a Drug named entity .
Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .@_@myalgia is not a named entity .
Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .@_@Thus is not a named entity .
Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .@_@parenteral is not a named entity .
Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .@_@be associated with is not a named entity .
A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin .@_@fatal rhabdomyolysis is an Adverse-Effect named entity .
A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin .@_@vasopressin is a Drug named entity .
A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin .@_@variceal is not a named entity .
A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin .@_@rhabdomyolysis is not a named entity .
A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin .@_@esophageal is not a named entity .
A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin .@_@treatment with is not a named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@vasodilation is an Adverse-Effect named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@impaired tissue perfusion is an Adverse-Effect named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@vasopressin is a Drug named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@perfusion is not a named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@contribute is not a named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@Idiosyncratic is not a named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@affinity is not a named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@involving is not a named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@distribution is not a named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@renin is not a named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@beds is not a named entity .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@beds , and is not a named entity .
Rhabdomyolysis associated with the use of intravenous vasopressin .@_@vasopressin is a Drug named entity .
Rhabdomyolysis associated with the use of intravenous vasopressin .@_@Rhabdomyolysis is an Adverse-Effect named entity .
These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .@_@rhabdomyolysis is an Adverse-Effect named entity .
These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .@_@vasopressin is a Drug named entity .
These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .@_@overlapping is not a named entity .
These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .@_@lead is not a named entity .
These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .@_@minority is not a named entity .
In one case , disulfiram was the only potential teratogen exposed to the fetus .@_@disulfiram is a Drug named entity .
In one case , disulfiram was the only potential teratogen exposed to the fetus .@_@teratogen is an Adverse-Effect named entity .
In one case , disulfiram was the only potential teratogen exposed to the fetus .@_@fetus is not a named entity .
Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies .@_@disulfiram is a Drug named entity .
Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies .@_@significant abnormalities is an Adverse-Effect named entity .
Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies .@_@trimester is not a named entity .
Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies .@_@Nonspecific is not a named entity .
Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies .@_@pregnancies is not a named entity .
Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies .@_@but significant is not a named entity .
Although the essential cause of PV is unclear , its onset has occasionally been associated with drug therapy , in particular penicillamine .@_@PV is an Adverse-Effect named entity .
Although the essential cause of PV is unclear , its onset has occasionally been associated with drug therapy , in particular penicillamine .@_@penicillamine is a Drug named entity .
Although the essential cause of PV is unclear , its onset has occasionally been associated with drug therapy , in particular penicillamine .@_@particular is not a named entity .
Although the essential cause of PV is unclear , its onset has occasionally been associated with drug therapy , in particular penicillamine .@_@unclear is not a named entity .
Although the essential cause of PV is unclear , its onset has occasionally been associated with drug therapy , in particular penicillamine .@_@occasionally is not a named entity .
Pemphigus vulgaris precipitated by glibenclamide therapy .@_@Pemphigus vulgaris is an Adverse-Effect named entity .
Pemphigus vulgaris precipitated by glibenclamide therapy .@_@glibenclamide is a Drug named entity .
Pemphigus vulgaris precipitated by glibenclamide therapy .@_@precipitated is not a named entity .
Pemphigus vulgaris precipitated by glibenclamide therapy .@_@vulgaris is not a named entity .
Pemphigus vulgaris precipitated by glibenclamide therapy .@_@Pemphigus is not a named entity .
Pemphigus vulgaris precipitated by glibenclamide therapy .@_@therapy . is not a named entity .
The patient described in this paper was a 78-year - old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy .@_@oral lesions of PV is an Adverse-Effect named entity .
The patient described in this paper was a 78-year - old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy .@_@glibenclamide is a Drug named entity .
The patient described in this paper was a 78-year - old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy .@_@78-year is not a named entity .
The patient described in this paper was a 78-year - old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy .@_@PV is not a named entity .
The patient described in this paper was a 78-year - old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy .@_@institution is not a named entity .
The patient described in this paper was a 78-year - old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy .@_@developed oral lesions of is not a named entity .
Piritrexim - induced pulmonary toxicity .@_@Piritrexim is a Drug named entity .
Piritrexim - induced pulmonary toxicity .@_@pulmonary toxicity is an Adverse-Effect named entity .
Piritrexim - induced pulmonary toxicity .@_@toxicity . is not a named entity .
The pulmonary toxicity is probably induced by piritrexim .@_@piritrexim is a Drug named entity .
The pulmonary toxicity is probably induced by piritrexim .@_@pulmonary toxicity is an Adverse-Effect named entity .
The pulmonary toxicity is probably induced by piritrexim .@_@probably induced is not a named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@respiratory dysfunction is an Adverse-Effect named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@piritrexim is a Drug named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@abnormal chest x - ray with diffuse interstitial opacities is an Adverse-Effect named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@ray is not a named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@analog is not a named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@opacities is not a named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@chest is not a named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@transitional is not a named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@pelvis is not a named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@methotrexate is not a named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@x is not a named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@interstitial opacities while on chemotherapy with piritrexim , a is not a named entity .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@on chemotherapy is not a named entity .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@adenosine is a Drug named entity .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@arrhythmia is an Adverse-Effect named entity .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@acceleration of the heart rate is an Adverse-Effect named entity .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@dangerous is not a named entity .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@acceleration is not a named entity .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@flutter is not a named entity .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@rate to a potentially dangerous is not a named entity .
Acceleration of ventricular response to atrial flutter after intravenous adenosine .@_@adenosine is a Drug named entity .
Acceleration of ventricular response to atrial flutter after intravenous adenosine .@_@Acceleration of ventricular response is an Adverse-Effect named entity .
Acceleration of ventricular response to atrial flutter after intravenous adenosine .@_@flutter is not a named entity .
Acceleration of ventricular response to atrial flutter after intravenous adenosine .@_@Acceleration is not a named entity .
Acceleration of ventricular response to atrial flutter after intravenous adenosine .@_@of ventricular response to is not a named entity .
Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate .@_@methotrexate is a Drug named entity .
Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate .@_@Lymphoma is an Adverse-Effect named entity .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@methotrexate is a Drug named entity .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@lymphoproliferative diseases is an Adverse-Effect named entity .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@coincidence is not a named entity .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@diseases is not a named entity .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@excluded is not a named entity .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@places is not a named entity .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@occurs is not a named entity .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@immunosuppression is not a named entity .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@risk of is not a named entity .
We report one case of non - Hodgkin lymphoma in a patient , with a 30-year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10-month period .@_@methotrexate is a Drug named entity .
We report one case of non - Hodgkin lymphoma in a patient , with a 30-year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10-month period .@_@non - Hodgkin lymphoma is an Adverse-Effect named entity .
We report one case of non - Hodgkin lymphoma in a patient , with a 30-year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10-month period .@_@weekly is not a named entity .
We report one case of non - Hodgkin lymphoma in a patient , with a 30-year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10-month period .@_@10-month is not a named entity .
We report one case of non - Hodgkin lymphoma in a patient , with a 30-year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10-month period .@_@30-year is not a named entity .
We report one case of non - Hodgkin lymphoma in a patient , with a 30-year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10-month period .@_@Hodgkin is not a named entity .
We report one case of non - Hodgkin lymphoma in a patient , with a 30-year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10-month period .@_@over a 10-month period is not a named entity .
Hepatotoxicity of paracetamol enhanced by ingestion of alcohol : report of two cases .@_@Hepatotoxicity is an Adverse-Effect named entity .
Hepatotoxicity of paracetamol enhanced by ingestion of alcohol : report of two cases .@_@paracetamol is a Drug named entity .
Hepatotoxicity of paracetamol enhanced by ingestion of alcohol : report of two cases .@_@alcohol is not a named entity .
Hepatotoxicity of paracetamol enhanced by ingestion of alcohol : report of two cases .@_@enhanced is not a named entity .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@hepatotoxic effects is an Adverse-Effect named entity .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@paracetamol is a Drug named entity .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@hepatotoxicity is an Adverse-Effect named entity .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@hepatotoxic is not a named entity .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@alcoholic is not a named entity .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@outlined is not a named entity .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@biochemistry is not a named entity .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@upon is not a named entity .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@susceptibility is not a named entity .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@remarked is not a named entity .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@outlined and is not a named entity .
Two fatal cases of poisoning by paracetamol are described .@_@paracetamol is a Drug named entity .
Two fatal cases of poisoning by paracetamol are described .@_@fatal is an Adverse-Effect named entity .
Two fatal cases of poisoning by paracetamol are described .@_@poisoning is not a named entity .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@prednisolone is a Drug named entity .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@Kaposi 's sarcoma is an Adverse-Effect named entity .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@KS is not a named entity .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@corticosteroid is not a named entity .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@pericardial is not a named entity .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@71-year is not a named entity .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@sole is not a named entity .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@foot is not a named entity .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@25 is not a named entity .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@Kaposi is not a named entity .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@a 71-year - is not a named entity .
Acute dystonic reaction with low - dose pimozide .@_@Acute dystonic reaction is an Adverse-Effect named entity .
Acute dystonic reaction with low - dose pimozide .@_@pimozide is a Drug named entity .
Acute dystonic reaction with low - dose pimozide .@_@dystonic is not a named entity .
Acute dystonic reaction with low - dose pimozide .@_@- dose pimozide is not a named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@pimozide is a Drug named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@acute dystonic reactions is an Adverse-Effect named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@thioridazine is a Drug named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@0.096 is not a named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@32 is not a named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@0.032 is not a named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@6.9-year is not a named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@kg is not a named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@repeated is not a named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@dystonic is not a named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@autistic is not a named entity .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@/ day and is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@atheroembolic acute renal failure is an Adverse-Effect named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@extrarenal manifestations is an Adverse-Effect named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@cholesterol crystal embolization is an Adverse-Effect named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@t - PA is a Drug named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@N is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@Engl is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@321:1270 is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@Med is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@t is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@extrarenal is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@1989 is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@embolization is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@atheroembolic is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@PA is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@crystal is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@J is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@cholesterol is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@Med 321:1270 , 1989 is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@renal failure following is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@is one case is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@manifestations ( N is not a named entity .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@Med 321:1270 is not a named entity .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@tissue - type plasminogen activator is a Drug named entity .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@Cholesterol crystal embolization is an Adverse-Effect named entity .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@renal failure is an Adverse-Effect named entity .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@plasminogen is not a named entity .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@embolization is not a named entity .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@crystal is not a named entity .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@Cholesterol is not a named entity .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@activator is not a named entity .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@with recombinant tissue is not a named entity .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@after therapy with recombinant tissue is not a named entity .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@- type is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@recombinant tissue - type plasminogen activator is a Drug named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@renal failure is an Adverse-Effect named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@cholesterol crystal embolization is an Adverse-Effect named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@t - PA is a Drug named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@plasminogen is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@PA is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@thrombolytic is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@crystal is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@embolization is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@t is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@activator is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@cholesterol is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@( t - is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@with intravenous recombinant tissue - type is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@( t - is not a named entity .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@tissue - is not a named entity .
Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .@_@multiform ventricular tachycardia is an Adverse-Effect named entity .
Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .@_@haloperidol is a Drug named entity .
Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .@_@Intravenous is not a named entity .
Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .@_@generally is not a named entity .
Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .@_@multiform is not a named entity .
Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .@_@tolerated is not a named entity .
Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .@_@ventricular tachycardia has is not a named entity .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@gold is a Drug named entity .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@mucocutaneous side effects is an Adverse-Effect named entity .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@compared is not a named entity .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@All is not a named entity .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@i is not a named entity .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@mucocutaneous is not a named entity .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@pretreatment is not a named entity .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@markedly is not a named entity .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@m is not a named entity .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@m gold therapy is not a named entity .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@mucocutaneous reactions is an Adverse-Effect named entity .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@gold is a Drug named entity .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@Use is not a named entity .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@you is not a named entity .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@mucocutaneous is not a named entity .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@go is not a named entity .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@How is not a named entity .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@can you is not a named entity .
Anterior spinal artery syndrome -- a complication of cervical intrathecal phenol injection .@_@phenol is a Drug named entity .
Anterior spinal artery syndrome -- a complication of cervical intrathecal phenol injection .@_@Anterior spinal artery syndrome is an Adverse-Effect named entity .
Anterior spinal artery syndrome -- a complication of cervical intrathecal phenol injection .@_@Anterior is not a named entity .
Anterior spinal artery syndrome -- a complication of cervical intrathecal phenol injection .@_@cervical is not a named entity .
Anterior spinal artery syndrome -- a complication of cervical intrathecal phenol injection .@_@cervical intrathecal phenol injection is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@phenol - glycerine is a Drug named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@anterior spinal artery syndrome is an Adverse-Effect named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@C4 is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@space is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@indicative is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@subarachnoid is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@0.3 is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@phenol is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@glycerine is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@ml is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@melanoma is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@-C5 is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@terminal is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@arm is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@cervical is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@which clinical manifestations , is not a named entity .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@the control of is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@worsening parkinsonism is an Adverse-Effect named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@risperidone is a Drug named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@feeding gastrostomy is an Adverse-Effect named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@removed is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@gastrostomy is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@home is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@feeding is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@clozapine is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@able is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@return is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@placement is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@nursing is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@parkinsonism is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@required is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@, but is not a named entity .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@return home is not a named entity .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@worsened motorically is an Adverse-Effect named entity .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@encephalopathy is an Adverse-Effect named entity .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@risperidone is a Drug named entity .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@clozapine is not a named entity .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@worsened is not a named entity .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@switched is not a named entity .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@motorically is not a named entity .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@risperidone treatment is not a named entity .
Azathioprine can cause severe myelosuppression .@_@Azathioprine is a Drug named entity .
Azathioprine can cause severe myelosuppression .@_@myelosuppression is an Adverse-Effect named entity .
Azathioprine - induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis .@_@Azathioprine is a Drug named entity .
Azathioprine - induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis .@_@myelosuppression is an Adverse-Effect named entity .
Azathioprine - induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis .@_@thiopurine is not a named entity .
Azathioprine - induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis .@_@methyltransferase is not a named entity .
The azathioprine dose was low ( 1 mg / kg ) and pancytopenia occurred after 56 days therapy .@_@pancytopenia is an Adverse-Effect named entity .
The azathioprine dose was low ( 1 mg / kg ) and pancytopenia occurred after 56 days therapy .@_@azathioprine is a Drug named entity .
The azathioprine dose was low ( 1 mg / kg ) and pancytopenia occurred after 56 days therapy .@_@56 is not a named entity .
Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .@_@azathioprine is a Drug named entity .
Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .@_@myelosuppression is an Adverse-Effect named entity .
Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .@_@300 is not a named entity .
Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .@_@methyltransferase is not a named entity .
Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .@_@frequency is not a named entity .
Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .@_@Thiopurine is not a named entity .
We describe the first documented case of azathioprine - induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease .@_@myelosuppression is an Adverse-Effect named entity .
We describe the first documented case of azathioprine - induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease .@_@azathioprine is a Drug named entity .
We describe the first documented case of azathioprine - induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease .@_@thiopurine is not a named entity .
We describe the first documented case of azathioprine - induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease .@_@methyltransferase is not a named entity .
Nabumetone - associated interstitial nephritis .@_@Nabumetone is a Drug named entity .
Nabumetone - associated interstitial nephritis .@_@interstitial nephritis is an Adverse-Effect named entity .
Nabumetone - associated interstitial nephritis .@_@associated interstitial is not a named entity .
She had been taking nabumetone for 6 months , but had discontinued the agent 2 weeks before admission due to progressive edema .@_@nabumetone is a Drug named entity .
She had been taking nabumetone for 6 months , but had discontinued the agent 2 weeks before admission due to progressive edema .@_@edema is an Adverse-Effect named entity .
She had been taking nabumetone for 6 months , but had discontinued the agent 2 weeks before admission due to progressive edema .@_@admission is not a named entity .
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea .@_@Acute myeloid leukemia is an Adverse-Effect named entity .
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea .@_@hydroxyurea is a Drug named entity .
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea .@_@thrombocythemia is not a named entity .
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea .@_@evolving is not a named entity .
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea .@_@myeloid leukemia evolving is not a named entity .
In this report , two cases of ET which evolved into AL without prior exposure to radiation or alkylating agents , and which were treated with long - term hydroxyurea therapy , are described .@_@hydroxyurea is a Drug named entity .
In this report , two cases of ET which evolved into AL without prior exposure to radiation or alkylating agents , and which were treated with long - term hydroxyurea therapy , are described .@_@AL is an Adverse-Effect named entity .
In this report , two cases of ET which evolved into AL without prior exposure to radiation or alkylating agents , and which were treated with long - term hydroxyurea therapy , are described .@_@evolved is not a named entity .
In this report , two cases of ET which evolved into AL without prior exposure to radiation or alkylating agents , and which were treated with long - term hydroxyurea therapy , are described .@_@alkylating is not a named entity .
In this report , two cases of ET which evolved into AL without prior exposure to radiation or alkylating agents , and which were treated with long - term hydroxyurea therapy , are described .@_@ET is not a named entity .
Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .@_@acute leukemia is an Adverse-Effect named entity .
Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .@_@hydroxyurea is a Drug named entity .
Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .@_@Prolonged is not a named entity .
Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .@_@ET is not a named entity .
Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .@_@patients with is not a named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@sudden death is an Adverse-Effect named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@cardiac effects is an Adverse-Effect named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@halofantrine is a Drug named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@involving is not a named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@border is not a named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@400 is not a named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@Burmese is not a named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@antimalarial is not a named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@Thai is not a named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@1993 is not a named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@, a is not a named entity .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@antimalarial treatment is not a named entity .
In the present paper , we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine .@_@halofantrine is a Drug named entity .
In the present paper , we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine .@_@QT interval was prolonged is an Adverse-Effect named entity .
In the present paper , we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine .@_@malaria is not a named entity .
In the present paper , we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine .@_@Japanese is not a named entity .
In the present paper , we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine .@_@vivax is not a named entity .
In the present paper , we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine .@_@treatment with halofantrine . is not a named entity .
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .@_@halofantrine is a Drug named entity .
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .@_@Prolongation of the QT interval is an Adverse-Effect named entity .
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .@_@malaria is not a named entity .
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .@_@vivax is not a named entity .
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .@_@Prolongation is not a named entity .
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .@_@Japanese is not a named entity .
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .@_@of the QT interval observed is not a named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@deaths is an Adverse-Effect named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@Halfan is a Drug named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@cardiac arrests is an Adverse-Effect named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@mefloquine is a Drug named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@pharmaceutical is not a named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@producing is not a named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@company is not a named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@thiamine is not a named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@arrests is not a named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@existing is not a named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@recent is not a named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@prolongation is not a named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@higher is not a named entity .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@of the is not a named entity .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@CHOP is a Drug named entity .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@Supravenous hyperpigmentation is an Adverse-Effect named entity .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@CD30 is not a named entity .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@anaplastic is not a named entity .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@Supravenous is not a named entity .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@hyperpigmentation is not a named entity .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@Ki-1 is not a named entity .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@chemotherapy of is not a named entity .
We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy .@_@supravenous hyperpigmentation is an Adverse-Effect named entity .
We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy .@_@CHOP is a Drug named entity .
We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy .@_@hyperpigmentation is not a named entity .
We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy .@_@supravenous is not a named entity .
We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy .@_@occurring after is not a named entity .
Phenytoin toxicity due to concomitant antituberculosis therapy .@_@Phenytoin is a Drug named entity .
Phenytoin toxicity due to concomitant antituberculosis therapy .@_@Phenytoin toxicity is an Adverse-Effect named entity .
Phenytoin toxicity due to concomitant antituberculosis therapy .@_@antituberculosis is not a named entity .
Phenytoin toxicity due to concomitant antituberculosis therapy .@_@antituberculosis therapy is not a named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@blood levels in the toxic range is an Adverse-Effect named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@phenytoin is a Drug named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@cent is not a named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@epileptogenic is not a named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@Seventy is not a named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@Unit is not a named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@Groote is not a named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@Schuur is not a named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@Emergency is not a named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@11.6 is not a named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@Hospital is not a named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@per is not a named entity .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@disorders seen at the Emergency Unit is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@phenytoin toxicity is an Adverse-Effect named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@phenytoin is a Drug named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@roughly is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@Slow is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@acetylators is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@population is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@50 is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@biochemical is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@antituberculosis is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@together is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@South is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@African is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@comprise is not a named entity .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@of the is not a named entity .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@phenytoin toxicity is an Adverse-Effect named entity .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@phenytoin is a Drug named entity .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@exhibiting is not a named entity .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@recent is not a named entity .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@makes is not a named entity .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@wide is not a named entity .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@epidemic is not a named entity .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@suspect is not a named entity .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@imperative is not a named entity .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@The wide is not a named entity .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@foscarnet is a Drug named entity .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@Nephrogenic diabetes insipidus is an Adverse-Effect named entity .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@renal tubular acidosis is an Adverse-Effect named entity .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@Nephrogenic is not a named entity .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@insipidus is not a named entity .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@acidosis secondary to is not a named entity .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@insipidus and renal is not a named entity .
No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .@_@foscarnet is a Drug named entity .
No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .@_@nephrogenic diabetes insipidus is an Adverse-Effect named entity .
No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .@_@nephrogenic is not a named entity .
No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .@_@No is not a named entity .
No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .@_@insipidus is not a named entity .
No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .@_@previously reported as is not a named entity .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@foscarnet is a Drug named entity .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@nephrogenic diabetes insipidus is an Adverse-Effect named entity .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@renal tubular acidosis is an Adverse-Effect named entity .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@link is not a named entity .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@nephrogenic is not a named entity .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@insipidus is not a named entity .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@temporal is not a named entity .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@patient developed both is not a named entity .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@patient developed both is not a named entity .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@thirst is an Adverse-Effect named entity .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@polyuria is an Adverse-Effect named entity .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@foscarnet is a Drug named entity .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@retinitis is not a named entity .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@immunodeficiency is not a named entity .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@CMV is not a named entity .
Choroidal hemorrhage associated with systemic tissue plasminogen activator .@_@tissue plasminogen activator is a Drug named entity .
Choroidal hemorrhage associated with systemic tissue plasminogen activator .@_@Choroidal hemorrhage is an Adverse-Effect named entity .
Choroidal hemorrhage associated with systemic tissue plasminogen activator .@_@activator is not a named entity .
Choroidal hemorrhage associated with systemic tissue plasminogen activator .@_@Choroidal is not a named entity .
Choroidal hemorrhage associated with systemic tissue plasminogen activator .@_@plasminogen is not a named entity .
Choroidal hemorrhage associated with systemic tissue plasminogen activator .@_@plasminogen activator is not a named entity .
Choroidal hemorrhage associated with systemic tissue plasminogen activator .@_@plasminogen activator . is not a named entity .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@hemorrhagic choroidal detachment is an Adverse-Effect named entity .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@hemorrhage is an Adverse-Effect named entity .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@tissue plasminogen activator is a Drug named entity .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@detachment is not a named entity .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@differential is not a named entity .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@plasminogen is not a named entity .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@activator is not a named entity .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@extent is not a named entity .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@choroidal is not a named entity .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@: The administration is not a named entity .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@choroidal detachment . is not a named entity .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@tissue plasminogen activator is a Drug named entity .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@spontaneous choroidal hemorrhage is an Adverse-Effect named entity .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@choroidal is not a named entity .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@plasminogen is not a named entity .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@67-year is not a named entity .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@determine is not a named entity .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@activator is not a named entity .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@of spontaneous choroidal is not a named entity .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@a myocardial infarction is not a named entity .
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .@_@Accelerated nodulosis is an Adverse-Effect named entity .
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .@_@methotrexate is a Drug named entity .
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .@_@nodulosis is not a named entity .
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .@_@juvenile is not a named entity .
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .@_@Accelerated is not a named entity .
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .@_@nodulosis during is not a named entity .
Although they had only a few nodules at diagnosis , the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients .@_@nodules is an Adverse-Effect named entity .
Although they had only a few nodules at diagnosis , the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients .@_@methotrexate is a Drug named entity .
Although they had only a few nodules at diagnosis , the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients .@_@start is not a named entity .
Although they had only a few nodules at diagnosis , the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients .@_@size is not a named entity .
Although they had only a few nodules at diagnosis , the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients .@_@number is not a named entity .
Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect .@_@extraarticular side effect is an Adverse-Effect named entity .
Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect .@_@methotrexate is a Drug named entity .
Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect .@_@extraarticular is not a named entity .
Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect .@_@treating is not a named entity .
Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect .@_@juvenile is not a named entity .
Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect .@_@must be aware is not a named entity .
The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other .@_@methotrexate is a Drug named entity .
The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other .@_@nodules is an Adverse-Effect named entity .
The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other .@_@hydroxychloroquine is not a named entity .
The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other .@_@arrested is not a named entity .
The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other .@_@regressed is not a named entity .
We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .@_@methotrexate is a Drug named entity .
We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .@_@accelerated nodulosis is an Adverse-Effect named entity .
We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .@_@accelerated is not a named entity .
We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .@_@polyarticular is not a named entity .
We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .@_@nodulosis is not a named entity .
We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .@_@juvenile is not a named entity .
We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .@_@We describe is not a named entity .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@methotrexate toxicity is an Adverse-Effect named entity .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@macrophage activation syndrome is an Adverse-Effect named entity .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@methotrexate is a Drug named entity .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@activation is not a named entity .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@macrophage is not a named entity .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@A macrophage activation is not a named entity .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@related to is not a named entity .
Jaundice induced by streptokinase .@_@Jaundice is an Adverse-Effect named entity .
Jaundice induced by streptokinase .@_@streptokinase is a Drug named entity .
Only a few reports of overt jaundice are associated with streptokinase .@_@streptokinase is a Drug named entity .
Only a few reports of overt jaundice are associated with streptokinase .@_@jaundice is an Adverse-Effect named entity .
Only a few reports of overt jaundice are associated with streptokinase .@_@overt is not a named entity .
Only a few reports of overt jaundice are associated with streptokinase .@_@Only is not a named entity .
Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin .@_@cisplatin is a Drug named entity .
Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin .@_@colitis is an Adverse-Effect named entity .
Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin .@_@same is not a named entity .
Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin .@_@recovered is not a named entity .
Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin .@_@vancomycin is not a named entity .
Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin .@_@relapse is not a named entity .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@C. difficile colitis is an Adverse-Effect named entity .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@cisplatin is a Drug named entity .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@C. is not a named entity .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@difficile is not a named entity .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@Based is not a named entity .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@concluded is not a named entity .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@thus is not a named entity .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@that cisplatin may is not a named entity .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@cisplatin is a Drug named entity .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@colitis is an Adverse-Effect named entity .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@carboplatin is not a named entity .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@alternative is not a named entity .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@malignancies is not a named entity .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@then is not a named entity .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@nor is not a named entity .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@relapse is not a named entity .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@neither is not a named entity .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@courses is not a named entity .
Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .@_@Clostridium difficile colitis is an Adverse-Effect named entity .
Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .@_@cisplatin is a Drug named entity .
Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .@_@difficile is not a named entity .
Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .@_@Clostridium is not a named entity .
Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .@_@associated with cisplatin is not a named entity .
Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .@_@C. difficile colitis is an Adverse-Effect named entity .
Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .@_@cisplatin is a Drug named entity .
Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .@_@malignancies is not a named entity .
Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .@_@6.1 is not a named entity .
Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .@_@C. is not a named entity .
Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .@_@difficile is not a named entity .
Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .@_@2 patients ( is not a named entity .
The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients .@_@Clostridium difficile colitis is an Adverse-Effect named entity .
The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients .@_@cisplatin is a Drug named entity .
The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients .@_@difficile is not a named entity .
The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients .@_@examine is not a named entity .
The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients .@_@purpose is not a named entity .
The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients .@_@Clostridium is not a named entity .
The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients .@_@cause of Clostridium is not a named entity .
A patient with severe cholestatic jaundice induced by captopril is presented .@_@captopril is a Drug named entity .
A patient with severe cholestatic jaundice induced by captopril is presented .@_@severe cholestatic jaundice is an Adverse-Effect named entity .
A patient with severe cholestatic jaundice induced by captopril is presented .@_@jaundice is not a named entity .
A patient with severe cholestatic jaundice induced by captopril is presented .@_@cholestatic is not a named entity .
A patient with severe cholestatic jaundice induced by captopril is presented .@_@patient with severe is not a named entity .
Captopril - associated " pseudocholangitis ' .@_@Captopril is a Drug named entity .
Captopril - associated " pseudocholangitis ' .@_@pseudocholangitis is an Adverse-Effect named entity .
Captopril is known to be associated with dermatologic , hematologic , and pulmonary adverse effects .@_@dermatologic , hematologic , and pulmonary adverse effects is an Adverse-Effect named entity .
Captopril is known to be associated with dermatologic , hematologic , and pulmonary adverse effects .@_@Captopril is a Drug named entity .
Captopril is known to be associated with dermatologic , hematologic , and pulmonary adverse effects .@_@hematologic is not a named entity .
Captopril is known to be associated with dermatologic , hematologic , and pulmonary adverse effects .@_@dermatologic is not a named entity .
Captopril is known to be associated with dermatologic , hematologic , and pulmonary adverse effects .@_@to be associated with dermatologic , hematologic , is not a named entity .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@liver damage is an Adverse-Effect named entity .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@atypical cholangitis is an Adverse-Effect named entity .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@captopril is a Drug named entity .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@cholangitis is not a named entity .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@captopril - is not a named entity .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@should be is not a named entity .
Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor .@_@nephrotic syndrome is an Adverse-Effect named entity .
Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor .@_@macrophage - colony - stimulating factor is a Drug named entity .
Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor .@_@myeloblastic is not a named entity .
Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor .@_@Development is not a named entity .
Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor .@_@macrophage is not a named entity .
Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor .@_@leukemia after is not a named entity .
Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor .@_@Development of nephrotic syndrome in a is not a named entity .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@M - CSF is a Drug named entity .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@nephrotic syndrome is an Adverse-Effect named entity .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@remitted is not a named entity .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@emphasized is not a named entity .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@whereas is not a named entity .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@remained is not a named entity .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@M is not a named entity .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@still is not a named entity .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@, including is not a named entity .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@completely remitted . is not a named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@M - CSF is a Drug named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@nephrotic syndrome is an Adverse-Effect named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@renal disease is an Adverse-Effect named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@accelerated is not a named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@glomerulus is not a named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@enhancing is not a named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@accumulation is not a named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@raised is not a named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@M is not a named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@macrophage is not a named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@glomerulus , is not a named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@raised that M is not a named entity .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@through enhancing is not a named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@M - CSF is a Drug named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@macrophage - related glomerular injury is an Adverse-Effect named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@histology is not a named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@M is not a named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@close is not a named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@evolutional is not a named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@macrophage is not a named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@glomerular is not a named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@proteinuria is not a named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@linkage is not a named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@CSF treatment and macrophage - is not a named entity .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@proteinuria and glomerular is not a named entity .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@macrophage - colony - stimulating factor is a Drug named entity .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@nephrotic syndrome is an Adverse-Effect named entity .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@M - CSF is a Drug named entity .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@macrophage is not a named entity .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@courses is not a named entity .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@M is not a named entity .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@AML is not a named entity .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@myeloblastic is not a named entity .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@of chemotherapy is not a named entity .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@of chemotherapy , including macrophage - is not a named entity .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@chemotherapy , including is not a named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@magnesium sulfate is a Drug named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@betamethasone is a Drug named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@nifedipine is a Drug named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@edema is an Adverse-Effect named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@terbutaline is a Drug named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@tocolysis is not a named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@sulfate is not a named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@On is not a named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@fifth is not a named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@labia is not a named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@magnesium is not a named entity .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@day of is not a named entity .
Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .@_@Milk - alkali syndrome is an Adverse-Effect named entity .
Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .@_@1,25(OH)2D is a Drug named entity .
Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .@_@Milk is not a named entity .
Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .@_@alkali is not a named entity .
Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .@_@hypoparathyroidism is not a named entity .
Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .@_@a patient with hypoparathyroidism is not a named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@calcitriol is a Drug named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@calcium carbonate is a Drug named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@milk - alkali syndrome is an Adverse-Effect named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@admissions is not a named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@milk is not a named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@alkali is not a named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@carbonate is not a named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@hypoparathyroidism is not a named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@presents is not a named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@hospital is not a named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@This article presents a is not a named entity .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@milk - is not a named entity .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@mesna is a Drug named entity .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@unresponsive is an Adverse-Effect named entity .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@ifosfamide is a Drug named entity .
CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion .@_@nonconvulsive status epilepticus is an Adverse-Effect named entity .
CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion .@_@ifosfamide is a Drug named entity .
CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion .@_@temporal is not a named entity .
CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion .@_@nonconvulsive is not a named entity .
CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion .@_@initiation of ifosfamide is not a named entity .
DISCUSSION : Central nervous system ( CNS ) toxicity has been described with ifosfamide , with most cases reported in the pediatric population .@_@ifosfamide is a Drug named entity .
DISCUSSION : Central nervous system ( CNS ) toxicity has been described with ifosfamide , with most cases reported in the pediatric population .@_@Central nervous system ( CNS ) toxicity is an Adverse-Effect named entity .
DISCUSSION : Central nervous system ( CNS ) toxicity has been described with ifosfamide , with most cases reported in the pediatric population .@_@population is not a named entity .
DISCUSSION : Central nervous system ( CNS ) toxicity has been described with ifosfamide , with most cases reported in the pediatric population .@_@Central is not a named entity .
DISCUSSION : Central nervous system ( CNS ) toxicity has been described with ifosfamide , with most cases reported in the pediatric population .@_@) toxicity has been described with ifosfamide is not a named entity .
Ifosfamide - induced nonconvulsive status epilepticus .@_@Ifosfamide is a Drug named entity .
Ifosfamide - induced nonconvulsive status epilepticus .@_@nonconvulsive status epilepticus is an Adverse-Effect named entity .
Ifosfamide - induced nonconvulsive status epilepticus .@_@nonconvulsive is not a named entity .
Ifosfamide - induced nonconvulsive status epilepticus .@_@- induced nonconvulsive is not a named entity .
OBJECTIVE : To describe a patient with ifosfamide - induced nonconvulsive status epilepticus .@_@nonconvulsive status epilepticus is an Adverse-Effect named entity .
OBJECTIVE : To describe a patient with ifosfamide - induced nonconvulsive status epilepticus .@_@ifosfamide is a Drug named entity .
OBJECTIVE : To describe a patient with ifosfamide - induced nonconvulsive status epilepticus .@_@nonconvulsive is not a named entity .
OBJECTIVE : To describe a patient with ifosfamide - induced nonconvulsive status epilepticus .@_@patient with ifosfamide is not a named entity .
This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .@_@nonconvulsive status epilepticus is an Adverse-Effect named entity .
This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .@_@ifosfamide is a Drug named entity .
This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .@_@nonconvulsive is not a named entity .
This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .@_@represents is not a named entity .
This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .@_@of nonconvulsive status is not a named entity .
Albendazole - induced pseudomembranous colitis .@_@pseudomembranous colitis is an Adverse-Effect named entity .
Albendazole - induced pseudomembranous colitis .@_@Albendazole is a Drug named entity .
Albendazole - induced pseudomembranous colitis .@_@pseudomembranous is not a named entity .
Albendazole - induced pseudomembranous colitis .@_@induced pseudomembranous is not a named entity .
Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .@_@metronidazole is a Drug named entity .
Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .@_@pseudomembranous colitis is an Adverse-Effect named entity .
Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .@_@link is not a named entity .
Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .@_@albendazole is not a named entity .
Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .@_@pseudomembranous is not a named entity .
Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .@_@the development is not a named entity .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@worsening diarrhea is an Adverse-Effect named entity .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@fever is an Adverse-Effect named entity .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@albendazole is a Drug named entity .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@abdominal pain is an Adverse-Effect named entity .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@diarrhea is not a named entity .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@, he is not a named entity .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@, he is not a named entity .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@TC is an Adverse-Effect named entity .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@Aluminum intoxication is an Adverse-Effect named entity .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@Aluminum is a Drug named entity .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@along is not a named entity .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@considered to is not a named entity .
Oculomotor disturbances associated with 5-fluorouracil chemotherapy .@_@Oculomotor disturbances is an Adverse-Effect named entity .
Oculomotor disturbances associated with 5-fluorouracil chemotherapy .@_@5-fluorouracil is a Drug named entity .
Oculomotor disturbances associated with 5-fluorouracil chemotherapy .@_@Oculomotor is not a named entity .
Oculomotor disturbances associated with 5-fluorouracil chemotherapy .@_@disturbances associated is not a named entity .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@ocular motor disturbances is an Adverse-Effect named entity .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@neurotoxicity is an Adverse-Effect named entity .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@5-FU is a Drug named entity .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@regional is not a named entity .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@primarily is not a named entity .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@stem is not a named entity .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@affecting is not a named entity .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@expression is not a named entity .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@motor is not a named entity .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@expression of regional is not a named entity .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@5-fluorouracil is a Drug named entity .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@cerebellar dysfunction is an Adverse-Effect named entity .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@5-FU is a Drug named entity .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@neurotoxicity is an Adverse-Effect named entity .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@colon is not a named entity .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@typical is not a named entity .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@5-FU ) is not a named entity .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@hypoglycaemia is an Adverse-Effect named entity .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@insulin is a Drug named entity .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@Assessment is not a named entity .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@creatinine is not a named entity .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@tetracosactrin is not a named entity .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@ratio is not a named entity .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@24-hour is not a named entity .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@cortisol is not a named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@adrenal suppression is an Adverse-Effect named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@fluticasone propionate is a Drug named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@growth retardation is an Adverse-Effect named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@retardation is not a named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@Six is not a named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@adrenal is not a named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@FINDINGS is not a named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@propionate is not a named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@suppression is not a named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@fluticasone is not a named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@: Six is not a named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@FINDINGS : is not a named entity .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@suppression . is not a named entity .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@Growth and adrenal suppression is an Adverse-Effect named entity .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@fluticasone propionate is a Drug named entity .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@Growth is not a named entity .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@fluticasone is not a named entity .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@adrenal is not a named entity .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@suppression is not a named entity .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@propionate is not a named entity .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@asthmatic is not a named entity .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@treated with high - is not a named entity .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@with high is not a named entity .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@fluticasone propionate is a Drug named entity .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@adrenal suppression is an Adverse-Effect named entity .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@growth may be retarded is an Adverse-Effect named entity .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@fluticasone is not a named entity .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@retarded is not a named entity .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@propionate is not a named entity .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@adrenal is not a named entity .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@INTERPRETATION is not a named entity .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@suppression may is not a named entity .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@: When is not a named entity .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@used , growth may is not a named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@Growth retardation is an Adverse-Effect named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@fluticasone propionate is a Drug named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@propionate is not a named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@fluticasone is not a named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@retardation is not a named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@Growth is not a named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@powder is not a named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@severely is not a named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@asthmatic is not a named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@dry is not a named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@children after is not a named entity .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@treatment ( is not a named entity .
Metipranolol associated granulomatous anterior uveitis : not so uncommon as thought .@_@granulomatous anterior uveitis is an Adverse-Effect named entity .
Metipranolol associated granulomatous anterior uveitis : not so uncommon as thought .@_@Metipranolol is a Drug named entity .
Metipranolol associated granulomatous anterior uveitis : not so uncommon as thought .@_@uveitis is not a named entity .
Metipranolol associated granulomatous anterior uveitis : not so uncommon as thought .@_@granulomatous is not a named entity .
Metipranolol associated granulomatous anterior uveitis : not so uncommon as thought .@_@not so uncommon is not a named entity .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@metripranolol is a Drug named entity .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@bilateral granulomatous anterior uveitis is an Adverse-Effect named entity .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@granulomatous is not a named entity .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@uveitis is not a named entity .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@drops is not a named entity .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@open is not a named entity .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@0.6 is not a named entity .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@case reports of bilateral is not a named entity .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@altered mental status is an Adverse-Effect named entity .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@desmopressin is a Drug named entity .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@hyponatremia is an Adverse-Effect named entity .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@seizures is an Adverse-Effect named entity .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@11 is not a named entity .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@intranasal is not a named entity .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@altered is not a named entity .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@mental is not a named entity .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@review of the is not a named entity .
Intranasal desmopressin - induced hyponatremia .@_@desmopressin is a Drug named entity .
Intranasal desmopressin - induced hyponatremia .@_@hyponatremia is an Adverse-Effect named entity .
Intranasal desmopressin - induced hyponatremia .@_@Intranasal is not a named entity .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@hyponatremia is an Adverse-Effect named entity .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@desmopressin is a Drug named entity .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@vague symptoms is an Adverse-Effect named entity .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@differential is not a named entity .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@part is not a named entity .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@vague is not a named entity .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@during desmopressin is not a named entity .
Within 24 hours of fluid restriction and cessation of desmopressin , her symptoms and hyponatremia resolved .@_@desmopressin is a Drug named entity .
Within 24 hours of fluid restriction and cessation of desmopressin , her symptoms and hyponatremia resolved .@_@hyponatremia is an Adverse-Effect named entity .
Within 24 hours of fluid restriction and cessation of desmopressin , her symptoms and hyponatremia resolved .@_@fluid is not a named entity .
Within 24 hours of fluid restriction and cessation of desmopressin , her symptoms and hyponatremia resolved .@_@Within is not a named entity .
Within 24 hours of fluid restriction and cessation of desmopressin , her symptoms and hyponatremia resolved .@_@restriction is not a named entity .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@hyponatremia is an Adverse-Effect named entity .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@desmopressin is a Drug named entity .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@syndrome of inappropriate antidiuretic hormone is an Adverse-Effect named entity .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@presumably is not a named entity .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@inappropriate is not a named entity .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@Without is not a named entity .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@antidiuretic is not a named entity .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@the hyponatremia , she was is not a named entity .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@clarithromycin is a Drug named entity .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@Uveitis is an Adverse-Effect named entity .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@ethambutol is a Drug named entity .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@rifabutin is a Drug named entity .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@Mycobacterium is not a named entity .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@intracellulare is not a named entity .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@avium is not a named entity .
Does acyclovir increase serum lithium levels ?@_@acyclovir is a Drug named entity .
Does acyclovir increase serum lithium levels ?@_@increase serum lithium levels is an Adverse-Effect named entity .
Does acyclovir increase serum lithium levels ?@_@lithium is not a named entity .
Does acyclovir increase serum lithium levels ?@_@Does is not a named entity .
Does acyclovir increase serum lithium levels ?@_@acyclovir increase serum lithium is not a named entity .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@acyclovir is a Drug named entity .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@lithium toxicity is an Adverse-Effect named entity .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@lithium is a Drug named entity .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@exhibited is not a named entity .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@Six is not a named entity .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@exhibited signs is not a named entity .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@increased serum lithium is an Adverse-Effect named entity .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@lithium is a Drug named entity .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@acyclovir is a Drug named entity .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@intravenously is not a named entity .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@/ kg may is not a named entity .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@lithium is a Drug named entity .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@acyclovir is a Drug named entity .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@lithium toxicity is an Adverse-Effect named entity .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@Until is not a named entity .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@closely is not a named entity .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@measuring is not a named entity .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@every is not a named entity .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@recommend is not a named entity .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@concurrently is not a named entity .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@available is not a named entity .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@with lithium is not a named entity .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@acyclovir is a Drug named entity .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@lithium is a Drug named entity .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@serum lithium level had increased is an Adverse-Effect named entity .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@measured is not a named entity .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@4-fold is not a named entity .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@had increased 4-fold during acyclovir is not a named entity .
Dapsone syndrome in cutaneous lupus erythematosus .@_@Dapsone is a Drug named entity .
Dapsone syndrome in cutaneous lupus erythematosus .@_@Dapsone syndrome is an Adverse-Effect named entity .
Dapsone syndrome in cutaneous lupus erythematosus .@_@lupus erythematosus is not a named entity .
Physicians should be aware of the potentially lethal side effects of dapsone .@_@lethal is an Adverse-Effect named entity .
Physicians should be aware of the potentially lethal side effects of dapsone .@_@dapsone is a Drug named entity .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@dapsone is a Drug named entity .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@dapsone reaction is an Adverse-Effect named entity .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@fatal is an Adverse-Effect named entity .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@outcome is not a named entity .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@cutaneous lupus is not a named entity .
A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder .@_@minoxidil is a Drug named entity .
A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder .@_@fatal interaction is an Adverse-Effect named entity .
A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder .@_@coagulation is not a named entity .
A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder .@_@illustrates is not a named entity .
A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder .@_@disorder . is not a named entity .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@NDI is an Adverse-Effect named entity .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@lithium is a Drug named entity .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@Nephrogenic diabetes insipidus is an Adverse-Effect named entity .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@Nephrogenic is not a named entity .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@) is a is not a named entity .
Potential mechanisms regarding the pathophysiology of lithium - associated CDI are discussed .@_@CDI is an Adverse-Effect named entity .
Potential mechanisms regarding the pathophysiology of lithium - associated CDI are discussed .@_@lithium is a Drug named entity .
Potential mechanisms regarding the pathophysiology of lithium - associated CDI are discussed .@_@pathophysiology is not a named entity .
Potential mechanisms regarding the pathophysiology of lithium - associated CDI are discussed .@_@regarding is not a named entity .
Potential mechanisms regarding the pathophysiology of lithium - associated CDI are discussed .@_@Potential is not a named entity .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@central diabetes insipidus is an Adverse-Effect named entity .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@CDI is an Adverse-Effect named entity .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@lithium is a Drug named entity .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@( CDI ) is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@polyuria is an Adverse-Effect named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@lithium is a Drug named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@importance is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@osmolality is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@simultaneous is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@interpreted is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@urine is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@appropriate is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@emphasizes is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@ensure is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@correct is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@measurement is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@evaluation is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@vasopressin is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@secure is not a named entity .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@direct is not a named entity .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@CDI is an Adverse-Effect named entity .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@NDI is an Adverse-Effect named entity .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@lithium is a Drug named entity .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@concurrently is not a named entity .
Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use .@_@lithium is a Drug named entity .
Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use .@_@Transient central diabetes insipidus is an Adverse-Effect named entity .
Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use .@_@setting is not a named entity .
Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use .@_@nephrogenic is not a named entity .
Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use .@_@insipidus in the setting is not a named entity .
We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI .@_@CDI is an Adverse-Effect named entity .
We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI .@_@lithium is a Drug named entity .
We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI .@_@setting is not a named entity .
We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI .@_@NDI is not a named entity .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@recombinant DNA human insulin is a Drug named entity .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@human insulin is a Drug named entity .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@lipoatrophy is an Adverse-Effect named entity .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@DNA is not a named entity .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@since is not a named entity .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@exclusively is not a named entity .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@IDDM is not a named entity .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@since the is not a named entity .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@DNA human insulin since is not a named entity .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@human insulin is a Drug named entity .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@lipoatrophy is an Adverse-Effect named entity .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@helpful is not a named entity .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@constitute is not a named entity .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@method is not a named entity .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@Jet is not a named entity .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@devices is not a named entity .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@injection devices is not a named entity .
Human insulin - induced lipoatrophy .@_@Human insulin is a Drug named entity .
Human insulin - induced lipoatrophy .@_@lipoatrophy is an Adverse-Effect named entity .
Human insulin - induced lipoatrophy .@_@Human is not a named entity .
Human insulin - induced lipoatrophy .@_@insulin - is not a named entity .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@lipoatrophy is an Adverse-Effect named entity .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@human insulin is a Drug named entity .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@injector is not a named entity .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@device is not a named entity .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@evaluate is not a named entity .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@efficacy is not a named entity .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@reversing is not a named entity .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@stopping is not a named entity .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@jet is not a named entity .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@of insulin is not a named entity .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@neurotoxic effects is an Adverse-Effect named entity .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@ofloxacin is a Drug named entity .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@safe is not a named entity .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@enhance is not a named entity .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@investigation is not a named entity .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@awareness is not a named entity .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@neurotoxic is not a named entity .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@Improved is not a named entity .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@may enhance is not a named entity .
Seizures associated with ofloxacin therapy .@_@Seizures is an Adverse-Effect named entity .
Seizures associated with ofloxacin therapy .@_@ofloxacin is a Drug named entity .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@renal insufficiency is an Adverse-Effect named entity .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@ofloxacin is a Drug named entity .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@seizures is an Adverse-Effect named entity .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@contributing is not a named entity .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@accumulation is not a named entity .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@timing is not a named entity .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@implicate is not a named entity .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@ofloxacin as is not a named entity .
We describe four patients who had seizures while receiving ofloxacin ; no other causes were evident .@_@seizures is an Adverse-Effect named entity .
We describe four patients who had seizures while receiving ofloxacin ; no other causes were evident .@_@ofloxacin is a Drug named entity .
We describe four patients who had seizures while receiving ofloxacin ; no other causes were evident .@_@evident is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@pinhead - sized facial pustules is an Adverse-Effect named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@erythroderma is an Adverse-Effect named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@tibial and facial oedema is an Adverse-Effect named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@abnormal liver function tests is an Adverse-Effect named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@fever is an Adverse-Effect named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin is a Drug named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin hypersensitivity syndrome is an Adverse-Effect named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@pinhead is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@pustules is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@tests is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@facial is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@sized is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@tibial is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@characteristic is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@PHS is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@, erythroderma , tibial is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@erythroderma , tibial is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@PHS ) including fever , is not a named entity .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@including fever , erythroderma is not a named entity .
Systemic corticosteroids in the phenytoin hypersensitivity syndrome .@_@phenytoin hypersensitivity syndrome is an Adverse-Effect named entity .
Systemic corticosteroids in the phenytoin hypersensitivity syndrome .@_@phenytoin is a Drug named entity .
Systemic corticosteroids in the phenytoin hypersensitivity syndrome .@_@Systemic is not a named entity .
Systemic corticosteroids in the phenytoin hypersensitivity syndrome .@_@hypersensitivity syndrome . is not a named entity .
A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis .@_@cyclophosphamide is a Drug named entity .
A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis .@_@sarcoma is an Adverse-Effect named entity .
A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis .@_@differentiated is not a named entity .
A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis .@_@poorly is not a named entity .
Sarcoma complicating therapy with cyclophosphamide .@_@Sarcoma is an Adverse-Effect named entity .
Sarcoma complicating therapy with cyclophosphamide .@_@cyclophosphamide is a Drug named entity .
A chronic reaction associated with long - term treatment with nitrofurantoin has also been reported and causes irreversible pulmonary fibrosis .@_@pulmonary fibrosis is an Adverse-Effect named entity .
A chronic reaction associated with long - term treatment with nitrofurantoin has also been reported and causes irreversible pulmonary fibrosis .@_@nitrofurantoin is a Drug named entity .
A chronic reaction associated with long - term treatment with nitrofurantoin has also been reported and causes irreversible pulmonary fibrosis .@_@causes irreversible is not a named entity .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@Acute pulmonary reactions is an Adverse-Effect named entity .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@pulmonary dysfunction is an Adverse-Effect named entity .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@nitrofurantoin is a Drug named entity .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@minor is not a named entity .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@or life - is not a named entity .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@side effect is not a named entity .
Despite the known pulmonary side effects of nitrofurantoin , there is no report of this toxicity occurring in pregnant patients .@_@nitrofurantoin is a Drug named entity .
Despite the known pulmonary side effects of nitrofurantoin , there is no report of this toxicity occurring in pregnant patients .@_@pulmonary side effects is an Adverse-Effect named entity .
Despite the known pulmonary side effects of nitrofurantoin , there is no report of this toxicity occurring in pregnant patients .@_@pregnant is not a named entity .
Despite the known pulmonary side effects of nitrofurantoin , there is no report of this toxicity occurring in pregnant patients .@_@report of this is not a named entity .
Nitrofurantoin - induced pulmonary toxicity during pregnancy : a report of a case and review of the literature .@_@Nitrofurantoin is a Drug named entity .
Nitrofurantoin - induced pulmonary toxicity during pregnancy : a report of a case and review of the literature .@_@pulmonary toxicity is an Adverse-Effect named entity .
Nitrofurantoin - induced pulmonary toxicity during pregnancy : a report of a case and review of the literature .@_@literature . is not a named entity .
We present a case of respiratory failure occurring in a woman at 16 weeks ' gestation who was being treated with nitrofurantoin for a urinary tract infection .@_@respiratory failure is an Adverse-Effect named entity .
We present a case of respiratory failure occurring in a woman at 16 weeks ' gestation who was being treated with nitrofurantoin for a urinary tract infection .@_@nitrofurantoin is a Drug named entity .
We present a case of respiratory failure occurring in a woman at 16 weeks ' gestation who was being treated with nitrofurantoin for a urinary tract infection .@_@tract is not a named entity .
We present a case of respiratory failure occurring in a woman at 16 weeks ' gestation who was being treated with nitrofurantoin for a urinary tract infection .@_@gestation is not a named entity .
We present a case of respiratory failure occurring in a woman at 16 weeks ' gestation who was being treated with nitrofurantoin for a urinary tract infection .@_@weeks ' is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone is a Drug named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome is an Adverse-Effect named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@infectious is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@include is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@jaundice is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@idiosyncratic is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@Less is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@mononucleosis is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@complaints is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@papillary is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@proteinuria is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@hypoalbuminemia is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@jaundice , nephrotic syndrome , renal is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@, cholestatic is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@, cholestatic is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@of leukopenia and agranulocytosis , is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@and agranulocytosis is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@papillary necrosis is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@, severe hypoalbuminemia is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@proteinuria , an infectious is not a named entity .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@Less common is not a named entity .
Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .@_@Methemoglobinemia is an Adverse-Effect named entity .
Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .@_@dapsone is a Drug named entity .
Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .@_@prominent is not a named entity .
Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .@_@does is not a named entity .
Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .@_@pallor is not a named entity .
Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .@_@finding is not a named entity .
Acetazolamide - accelerated anticonvulsant osteomalacia .@_@osteomalacia is an Adverse-Effect named entity .
Acetazolamide - accelerated anticonvulsant osteomalacia .@_@Acetazolamide is a Drug named entity .
Acetazolamide - accelerated anticonvulsant osteomalacia .@_@accelerated is not a named entity .
Acetazolamide - accelerated anticonvulsant osteomalacia .@_@anticonvulsant is not a named entity .
Acetazolamide may have accelerated the development of osteomalacia by several mechanisms , including increased renal calcium excretion .@_@Acetazolamide is a Drug named entity .
Acetazolamide may have accelerated the development of osteomalacia by several mechanisms , including increased renal calcium excretion .@_@osteomalacia is an Adverse-Effect named entity .
Acetazolamide may have accelerated the development of osteomalacia by several mechanisms , including increased renal calcium excretion .@_@excretion is not a named entity .
Acetazolamide may have accelerated the development of osteomalacia by several mechanisms , including increased renal calcium excretion .@_@accelerated is not a named entity .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@phenobarbital is a Drug named entity .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@phenytoin is a Drug named entity .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@acetazolamide is a Drug named entity .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@Severe osteomalacia is an Adverse-Effect named entity .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@osteomalacia is not a named entity .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@congeners is not a named entity .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@epileptic is not a named entity .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@- term is not a named entity .
The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate .@_@encephalopathy is an Adverse-Effect named entity .
The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate .@_@methotrexate is a Drug named entity .
The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate .@_@delayed is not a named entity .
The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate .@_@9 is not a named entity .
The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate .@_@22 is not a named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@leukoencephalopathy is an Adverse-Effect named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@methotrexate is a Drug named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@hydrocephalus is an Adverse-Effect named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@histories is not a named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@cranial is not a named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@prophylaxis is not a named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@irradiation is not a named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@brothers is not a named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@twin is not a named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@concordant is not a named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@identical is not a named entity .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@intrathecally is not a named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@loperamide is a Drug named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@loperamide poisoning is an Adverse-Effect named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@recorded is not a named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@poisoning is not a named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@Toxicologiques is not a named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@conducted is not a named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@Centre is not a named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@retrospective is not a named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@40 is not a named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@d'Informations is not a named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@Veterinaires is not a named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@National is not a named entity .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@recorded at is not a named entity .
Loperamide poisoning in the dog .@_@Loperamide is a Drug named entity .
Loperamide poisoning in the dog .@_@Loperamide poisoning is an Adverse-Effect named entity .
Loperamide poisoning in the dog .@_@poisoning is not a named entity .
Loperamide poisoning in the dog .@_@dog is not a named entity .
Loperamide poisoning in the dog .@_@the dog is not a named entity .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@lithium carbonate is a Drug named entity .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@Creutzfeldt - Jakob like syndrome is an Adverse-Effect named entity .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@Creutzfeldt is not a named entity .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@carbonate is not a named entity .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@Jakob is not a named entity .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@67-year is not a named entity .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@during lithium carbonate treatment . is not a named entity .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@developed a is not a named entity .
Lithium - induced Creutzfeldt - Jakob syndrome .@_@Creutzfeldt - Jakob syndrome is an Adverse-Effect named entity .
Lithium - induced Creutzfeldt - Jakob syndrome .@_@Lithium is a Drug named entity .
Lithium - induced Creutzfeldt - Jakob syndrome .@_@Creutzfeldt is not a named entity .
Lithium - induced Creutzfeldt - Jakob syndrome .@_@Jakob is not a named entity .
Lithium - induced Creutzfeldt - Jakob syndrome .@_@Lithium - induced Creutzfeldt is not a named entity .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Lithium is a Drug named entity .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Lithium neurotoxicity is an Adverse-Effect named entity .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Creutzfeldt - Jakob disease is an Adverse-Effect named entity .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@differential is not a named entity .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Creutzfeldt is not a named entity .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@valuable is not a named entity .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Jakob is not a named entity .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@electroencephalograms is not a named entity .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@serial is not a named entity .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@should be considered in is not a named entity .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@neurotoxicity should is not a named entity .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@lithium is a Drug named entity .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@Creutzfeldt - Jakob syndrome is an Adverse-Effect named entity .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@them is not a named entity .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@Creutzfeldt is not a named entity .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@half is not a named entity .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@Several is not a named entity .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@Jakob is not a named entity .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@date is not a named entity .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@syndrome have been reported is not a named entity .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@vecuronium is a Drug named entity .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@magnesium is a Drug named entity .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@protracted neuromuscular block is an Adverse-Effect named entity .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@differential is not a named entity .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@severely is not a named entity .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@noninvasive is not a named entity .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@neuromuscular is not a named entity .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@preeclamptic is not a named entity .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@protracted is not a named entity .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@method is not a named entity .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@noninvasive method in is not a named entity .
